Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D002318: Cardiovascular Diseases

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (65)


Name (Synonyms) Correlation
drug895 Convalescent Plasma Wiki 0.46
drug893 Convalescent COVID 19 Plasma Wiki 0.26
drug900 Convalescent Plasma Transfusion Wiki 0.26
Name (Synonyms) Correlation
drug896 Convalescent Plasma (CP) Wiki 0.26
drug903 Convalescent Plasma of patients with COVID-19 Wiki 0.19
drug1566 Hydroxychloroquine, Doxycycline Wiki 0.19
drug1971 Masked Saline Placebo Wiki 0.19
drug4003 non-interventional Wiki 0.19
drug1102 Drugs and supportive care Wiki 0.19
drug1425 Growth Mindset Wiki 0.19
drug1062 Digital cardiac Counseling Wiki 0.19
drug3386 Tele-medicine platform Wiki 0.19
drug2246 Non-invasive cardiac imaging Wiki 0.19
drug626 COVID visitation restrictions Wiki 0.19
drug631 COVID-19 Breastfeeding Support Wiki 0.19
drug1562 Hydroxychloroquine, Azithromycin Wiki 0.19
drug4035 placebo (hartmann plus albumine) Wiki 0.19
drug2997 SLEDD with a L-MOD Wiki 0.19
drug3416 Temporarily holding the RAAS inhibitor [intervention] Wiki 0.19
drug882 Control (albumin 5%) Wiki 0.19
drug315 Assessment of cardiovascular diseases and cardiovascular risk factors Wiki 0.19
drug891 Control swab Wiki 0.19
drug1688 Interferon-Alpha2B Wiki 0.19
drug1565 Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki 0.19
drug1167 Electrocardiogram, telemetry, echocardiogram, laboratory values Wiki 0.19
drug3198 Standard Donor Plasma Wiki 0.19
drug26 1: discontinuation of RAS blocker therapy Wiki 0.19
drug3326 Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) Wiki 0.19
drug2802 Random Donor Plasma Wiki 0.19
drug1563 Hydroxychloroquine, Clindamycin Wiki 0.19
drug905 Convalescent Serum Wiki 0.19
drug901 Convalescent Plasma as Therapy for Covid-19 patients Wiki 0.19
drug660 COVID-19 exposure Wiki 0.19
drug3997 non Wiki 0.19
drug17 14C-lazertinib Wiki 0.19
drug3194 Standard COVID-19 therapies Wiki 0.19
drug1564 Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki 0.19
drug2224 No interverntion Wiki 0.19
drug37 2: continuation of RAS blocker therapy Wiki 0.19
drug2760 RAAS inhibitor [continued standard of care] Wiki 0.19
drug2485 Phone-call screening and management by a medical student/general practitioner tandem Wiki 0.19
drug2685 Prototype swab Wiki 0.19
drug3196 Standard Care Therapy Wiki 0.19
drug1613 Icosapent ethyl Wiki 0.13
drug897 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.13
drug1312 Fiberoptic Endoscopic Evaluation of Swallowing Wiki 0.13
drug889 Control group Wiki 0.11
drug4012 observational Wiki 0.11
drug3297 Supportive Care Wiki 0.11
drug804 Clinical data Wiki 0.11
drug1683 Interferon Beta-1A Wiki 0.09
drug963 DAS181 Wiki 0.08
drug1874 Losartan Wiki 0.07
drug3022 Saline Wiki 0.06
drug881 Control Wiki 0.06
drug2037 Methylprednisolone Wiki 0.05
drug1196 Enoxaparin Wiki 0.05
drug908 Convalescent plasma Wiki 0.04
drug3231 Standard of care Wiki 0.04
drug2855 Remdesivir Wiki 0.04
drug1745 Ivermectin Wiki 0.04
drug3485 Tocilizumab Wiki 0.03
drug3221 Standard of Care Wiki 0.03
drug1520 Hydroxychloroquine Wiki 0.02
drug2505 Placebo Wiki 0.01

Correlated MeSH Terms (33)


Name (Synonyms) Correlation
D015428 Myocardial Reperfusion Injury NIH 0.19
D015427 Reperfusion Injury NIH 0.19
D006333 Heart Failure NIH 0.18
Name (Synonyms) Correlation
D003327 Coronary Disease NIH 0.14
D013896 Thoracic Diseases NIH 0.13
D000787 Angina Pectoris NIH 0.13
D050197 Atherosclerosis NIH 0.13
D000073296 Noncommunicable Diseases NIH 0.13
D054143 Heart Failure, Systolic NIH 0.13
D006331 Heart Diseases NIH 0.11
D009202 Cardiomyopathies NIH 0.11
D014029 Tobacco Use Disorder NIH 0.11
D003680 Deglutition Disorders NIH 0.09
D003693 Delirium NIH 0.08
D054058 Acute Coronary Syndrome NIH 0.08
D006973 Hypertension NIH 0.08
D001523 Mental Disorders NIH 0.07
D000066553 Problem Behavior NIH 0.07
D050177 Overweight NIH 0.07
D003324 Coronary Artery Disease NIH 0.07
D008173 Lung Diseases, Obstructive NIH 0.05
D002908 Chronic Disease NIH 0.05
D009203 Myocardial Ischemia NIH 0.05
D008171 Lung Diseases, NIH 0.04
D014947 Wounds and Injuries NIH 0.03
D012141 Respiratory Tract Infections NIH 0.03
D016638 Critical Illness NIH 0.02
D011024 Pneumonia, Viral NIH 0.02
D007239 Infection NIH 0.02
D013577 Syndrome NIH 0.02
D003141 Communicable Diseases NIH 0.01
D011014 Pneumonia NIH 0.01
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (14)


Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.97
HP:0001681 Angina pectoris HPO 0.13
HP:0002621 Atherosclerosis HPO 0.13
Name (Synonyms) Correlation
HP:0001635 Congestive heart failure HPO 0.12
HP:0001638 Cardiomyopathy HPO 0.11
HP:0000822 Hypertension HPO 0.09
HP:0002015 Dysphagia HPO 0.09
HP:0001677 Coronary artery atherosclerosis HPO 0.08
HP:0000708 Behavioral abnormality HPO 0.07
HP:0006536 Pulmonary obstruction HPO 0.06
HP:0001658 Myocardial infarction HPO 0.05
HP:0002088 Abnormal lung morphology HPO 0.04
HP:0011947 Respiratory tract infection HPO 0.04
HP:0002090 Pneumonia HPO 0.01

Clinical Trials

Navigate: Correlations   HPO

There are 29 clinical trials


1 Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China

Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

NCT04255940
Conditions
  1. Cardiovascular Death; Major Adverse Cardiovascular Events
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Cardiovascular Death

Time: 3 months

Secondary Outcomes

Measure: Major Adverse Cardiovascular Events

Time: 3 months

Measure: Times From symptom onset to hospital arrival

Time: 3 months

Measure: Anxiety

Time: 3 months
2 Retrospective Study of Myocardial Damage in COVID-19

This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.

NCT04312464
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
Interventions
  1. Other: non
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: The myocardial injury incidence of COVID-19 patients

Measure: The myocardial injury incidence

Time: 75 days

Description: The risk factors analysis for the death of COVID-19 patients

Measure: The risk factors analysis for the death

Time: 75 days

Secondary Outcomes

Description: The clinical characteristics description of COVID-19 patients

Measure: Clinical characteristics

Time: 75 days

Description: The clinical course description of COVID-19 patients

Measure: Clinical course

Time: 75 days

Description: The clinical characteristics and prognosis analysis in different cardiovascular comorbidity of COVID-19 patients

Measure: Cardiovascular comorbidity

Time: 75 days

Description: Analysis of causes of death in COVID-19 patients

Measure: Analysis of causes of death

Time: 75 days
3 Time of Recovery and Prognostic Factors of COVID-19 Pneumonia

It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.

NCT04324684
Conditions
  1. Pneumonia, Viral
  2. Hypertension
  3. Diabetes Mellitus
  4. Obesity
  5. Cardiovascular Diseases
  6. Obstructive Lung Disease
MeSH:Pneumonia, Viral Pneumonia Lung Diseases Lung Diseases, Obstructive Cardiovascular Diseases
HPO:Abnormal lung morphology Abnormality of the cardiovascular system Pneumonia Pulmonary obstruction

Primary Outcomes

Description: mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.

Measure: rate of recovery

Time: 3 weeks

Secondary Outcomes

Description: comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications

Measure: time to improvement

Time: 3 weeks

Description: the efficacy of different pharmaceutical treatment against Covid-19

Measure: efficacy of treatments

Time: 3 weeks

Description: liver, kidney or multiorgan failure, cardiac failure

Measure: organ failure

Time: 3 weeks
4 Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY

CAPACITY (www.capacity-covid.eu) is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organisation) in response to the emerging outbreak of COVID-19.

NCT04325412
Conditions
  1. COVID-19; Cardiovascular Diseases
MeSH:Coronaviru Coronavirus Infections Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: The incidence of cardiovascular complications in patients with COVID-19

Time: 30 days
5 Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic

Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.

NCT04325867
Conditions
  1. Angina Pectoris
  2. Acute Coronary Syndrome
  3. Coronary Syndrome
  4. Coronary Artery Disease
  5. Angioplasty
  6. Stent Restenosis
  7. Hypertension
  8. Heart Failure, Systolic
  9. Depression, Anxiety
  10. Covid-19
  11. Isolation, Social
Interventions
  1. Other: Tele-medicine platform
MeSH:Heart Failure Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Angina Pectoris Heart Failure, Systolic Syndrome
HPO:Abnormality of the cardiovascular system Angina pectoris Congestive heart failure Coronary artery atherosclerosis Left ventricular dysfunction Myocardial infarction Right ventricular failure

Primary Outcomes

Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context

Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients

Time: 6 months

Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);

Measure: Number of patients included in this platform

Time: 6 months

Secondary Outcomes

Description: Will be the number of sessions per patient multiplied with the number of patients included

Measure: Number of consultations/sessions given

Time: 6 months
6 Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

NCT04327479
Conditions
  1. Cardiovascular Diseases
  2. Cardiovascular Risk Factor
  3. SARS
Interventions
  1. Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: mortality of any cause

Measure: All-cause mortality

Time: During 1 year follow-up

Secondary Outcomes

Description: mortality of any cause

Measure: 30-day mortality

Time: Within 30 days after inclusion

Description: Myocardial infarction, stroke, or CV death

Measure: Major adverse cardiovascular events

Time: During 1 year follow-up
7 ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study

Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19. Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death. Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19. It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.

NCT04329195
Conditions
  1. History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection
Interventions
  1. Drug: 1: discontinuation of RAS blocker therapy
  2. Drug: 2: continuation of RAS blocker therapy
MeSH:Infection Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)

Time: from day 0 to day 28 or hospital discharge

Secondary Outcomes

Measure: Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28

Time: at day 28

Measure: Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.

Time: at days 7, 14 and 28

Measure: Number of days alive free of oxygen.

Time: from day 0 to day 28 or hospital discharge

Measure: Number of days alive outside hospital until day28

Time: at day28

Measure: Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28

Time: at day28

Measure: Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28

Time: at day28

Measure: Number of days alive free of ICU admission until day28

Time: at day28

Measure: Rate of all-cause mortality at day 28

Time: at day 28

Measure: Rate of cardiovascular death at day 28

Time: at day 28

Measure: Number of days alive free of acute kidney injury until hospital discharge

Time: at day 28 to hospital discharge
8 Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19

Multicentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.

NCT04331574
Conditions
  1. COVID-19
  2. Hypertension
  3. Cardiovascular Diseases
MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension

Primary Outcomes

Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.

Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Time: 3 months

Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19

Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Time: 3 months

Secondary Outcomes

Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity

Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity

Time: 3 months
9 Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first reports of COVID-19 came from Wuhan, China in December of 2019. Since then, the disease has spread rapidly around the globe, accounting for thousands of deaths in multiple countries. On March 11th, 2020, the World Health Organization declared COVID-19 as a pandemic. Although COVID-19 manifests primarily as a respiratory illness, several cardiovascular implications have been reported related to its natural course and treatment. Its exact effect on the cardiovascular system though is currently unknown. Therefore, we propose a retrospective, observational, case-control study looking for cardiovascular manifestations of COVID-19, including laboratory evidence of myocardial injury, electrocardiographic changes, arrhythmias and echocardiographic abnormalities. Hospitalized patients admitted with fever, cough, sore throat, and/or dyspnea who were tested positive for SARS-CoV-2 will be included in our study and will be matched based on their age and gender with patients admitted with similar symptoms who tested negative for SARS-CoV-2. The electronic medical charts of the study subjects will be reviewed and relevant demographic, clinical, laboratory and imaging findings will be deidentified and recorded. Since our study will be a retrospective chart review study it carries minimal risk for the patients and the investigators. Cardiovascular disease associated with COVID-19 might be contributing to the high mortality rates and its recognition will allow for prevention, early diagnosis and appropriate treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.

NCT04335630
Conditions
  1. Cardiovascular Diseases
  2. COVID
Interventions
  1. Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.

Time: One year

Secondary Outcomes

Measure: Prevalence of pericarditis, pericardial effusion, valvular disease.

Time: One year

Measure: Identification of characteristic electrocardiographic patterns related to COVID-19

Time: One year

Measure: Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.

Time: One year

Measure: Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19

Time: One year

Measure: Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19

Time: One year

Measure: Role of insurance type on clinical outcomes of patients with COVID-19

Time: One year

Measure: Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications

Time: One year

Measure: Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications

Time: One year
10 The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury

COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.

NCT04340921
Conditions
  1. Cardiovascular Disease Acute
  2. Cardiomyopathies
  3. COVID
Interventions
  1. Biological: COVID-19 exposure
MeSH:Cardiovascular Diseases Cardiomyopathies
HPO:Abnormality of the cardiovascular system Cardiomyopathy

Primary Outcomes

Description: T-cell immunophenotype

Measure: T-cell immunophenotype

Time: 12 months from enrollment

Secondary Outcomes

Description: death, survival to discharge

Measure: Mortality

Time: 12 months from enrolment

Description: Admission to the intensive care

Measure: ITU admission

Time: 12 months from enrolment

Description: Defined by troponin rise to >99th centile

Measure: Myocardial injury

Time: 12 months from enrolment
11 Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial

Following the announcement of the containment of the population due to the COVID-19 epidemic on March 17, 2020 in France, a notable decrease in the number of consultations in general practice was reported. Patients no longer contact their general practitioner, including those with regular follow-up for one or more chronic conditions. This observation raised worries since it could lead to delay or failure in detecting decompensations / complications of these chronic conditions by a lack of recourse to care. Thus, an urgent message from the National Health Department (Direction Générale de la Santé - DGS) was adressed on April 8, 2020 to the health professionals regarding the organization of care aside from COVID-19. The main recommendation was "that the personal physician or the corresponding specialist should contact the most fragile patients with chronic condition to ensure follow-up and detect any risk of decompensation ". Such fragile patients are in great numbers, up to more than 200 for an average general practitioner. Therefore, although this recommendation is regarded as "essential in view of the health needs of the population", it will prove quite difficult to follow without the help of a skilled external assistance that can be quickly mobilized. The COVIQUEST project is a cluster randomized trial in general practice designed to assess the optimizationg of the screening and management of patients with chronic condition at risk of decompensation through a collaboration between the general practitioner and a medical student. The trial will focus on patients wit cardiovascular conditions aged 70 or more and patients with mental health conditions. These conditions are both highly prevalent in general practice and both at risk of severe short-term complications. Practices will be randomly assigned to a group (A or B). In group A, students will start by contacting patients with cardiovascular conditions; in group B they will start by contacting patients patients with mentral health conditions. The students will call these patients on the phone and ask them specific questions about their health, their needs, and if they want their general practitioner to call them back. The student will then transmit this information to the general practitioner who will decide on the best care to offer the patient. The primary outcome is defined as the occurrence of hospitalization during a one-month period after the phone call. It will be collected by a second phone call from the medical student. This time, all patients will be contacted, i.e. both patients with mental illness and cardiovascular patients, whatever the group. Thus, patients allocated to the control groups (i.e. patients with mental illness from group A and cardiovascular patients from group B) will also benefit from the intervention at 1 month: again, students will ask patients about their health and whether they want their general practitioner to call them back. This approach has several advantages: 1. all patients will benefit from a phone call, in accordance with the recommendations of the DGS, 2. the involvement of students, competent in medical interviews and quickly mobilizable, will help general practitioners, on the front line of many missions, without any health risk linked to the contagiousness of COVID-19 for students, 3. randomizing the call order will allow to assess with a high level of evidence the impact of such an organization on hospitalizations, for two families of diseases with high prevalence. The trial will involve at least nine French regions. Considering that the general practitioner's patient base numbers an average of 110 patients with chronic cardiovascular disease or chronic mental illness, and that at least 25 general practitioners per region participate in the study, we can expect that 22,000 patients will benefit from the intervention of this study.

NCT04359875
Conditions
  1. Cardiovascular Diseases
  2. Mental Disorder
Interventions
  1. Behavioral: Phone-call screening and management by a medical student/general practitioner tandem
MeSH:Cardiovascular Diseases Mental Disorders
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Hospitalization over a one month period. The primary outcome will be collected by a phone call from a medical student to the patient 1 month after randomization date. Hospitalizations (date, location, length, if available, and reason) will be collected. Because there will be many patients to be called for each practitioner, we expect these phone call to occur within a few days after day 28.

Measure: Hospitalization(s) at 1 month

Time: 1 month

Secondary Outcomes

Description: In the experimental group only: proportion of patients for whom the practitioner had to call back after the medical student had phoned (just after allocation of the practice to the experimental group) at 1 month.

Measure: Phone-call from the general practitioner (in the experimental group only)

Time: 1 month

Description: Mortality will be reported after checking with the city of the patient's home if there is no response to the phone call

Measure: Mortality at 1 month

Time: 1 month

Description: Number of general practitioner consultations and teleconsultations (and time of general practitioner consultation, i.e. during the containment period or not) using data from the French Health National (SNDS) Database

Measure: Use of primary care

Time: 6 months

Description: Number of consultations with another medical specialist (and time of consultation, i.e. during the containment period or not) using data from the French Health National (SNDS) Database

Measure: Use of secondary care

Time: 6 months

Description: Number of prescriptions related to the chronic disease that were dispensed by the pharmacy using data from the French Health National (SNDS) Database

Measure: Number of prescriptions related to the chronic disease dispensed by the pharmacy

Time: 6 months

Description: Number of hospitalizations using data from the French Health National (SNDS) Database

Measure: Number of hospitalization(s)

Time: 6 months

Description: Time to hospitalization using data from the French Health National (SNDS) Database

Measure: Time to hospitalization(s)

Time: 6 months

Description: Hospitalization duration using data from the French Health National (SNDS) Database

Measure: Hospitalization(s)' durations

Time: 6 months

Description: Reason for hospitalization using data from the French Health National (SNDS) Database

Measure: Reasons for hospitalization(s)

Time: 6 months

Description: Number of deaths using data from the French Health National (SNDS) Database

Measure: Mortality at 6 months

Time: 6 months

Description: Only for patients in the COVIQuest_CV sub-trial: Cardiovascular events (MACE): nonfatal stroke, nonfatal myocardial infarction, cardiovascular death and hospitalization for heart failure using data from the French Health National (SNDS) Database

Measure: Cardiovascular events (MACE)

Time: 6 months

Description: Only for patients in the COVIQuest_MH sub-trial: Psychotropic drugs consumption using data from the French Health National (SNDS) Database

Measure: Psychotropic drugs

Time: 6 months
12 Long-term Effects of Coronavirus 2019 Disease on the Cardiovascular System in Patients Who Have Undergone a Diagnostic Nasopharyngeal Swab for SARS-CoV-2. CV COVID-19 Registry

Patients presenting with the coronavirus-2019 disease (COVID-19) have a very high risk of cardiovascular adverse events, including death from cardiovascular causes. Unfortunately, there are no reliable statistics on the frequency and severity of these complications during the index hospitalization. Moreover, the long-term cardiovascular outcomes of these patients are entirely unknown. The investigators aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and determine their long-term cardiovascular outcomes.

NCT04359927
Conditions
  1. Sars-CoV2
  2. Covid19
  3. Cardiovascular Diseases
  4. Cardiovascular Risk Factor
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Cardiovascular mortality is defined according to the Academic Research Consortium-2 and will be independently adjudicated by a Clinical Events Committee.

Measure: Cardiovascular mortality

Time: 1-year

Secondary Outcomes

Description: Acute myocardial infarction is defined according to the Academic Research Consortium-2.

Measure: Acute myocardial infarction

Time: 1-year

Description: Stroke is defined according to the Academic Research Consortium-2.

Measure: Stroke

Time: 1-year

Other Outcomes

Description: Documented hospital admission due to heart failure

Measure: Heart failure hospitalization

Time: 1-year

Description: Documented by a chest computed tomography

Measure: Pulmonary embolism

Time: 1-year

Description: Documented hospital admission due to any cardiac arrhythmia

Measure: Cardiac arrhythmias

Time: 1-year
13 How Are You Coping? Assessing the Psychological, Social, and Economic Impacts of an Emerging Pandemic

A dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.

NCT04369690
Conditions
  1. COVID-19
  2. Chronic Disease
  3. Psychiatric Disorder
  4. Cardiovascular Diseases
MeSH:Cardiovascular Diseases Chronic Disease Mental Disorders Problem Behavior
HPO:Abnormality of the cardiovascular system Behavioral abnormality

Primary Outcomes

Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)

Measure: Mental health - Stress

Time: through study completion, estimated to 8 months

Description: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)

Measure: Mental health - Anxiety

Time: through study completion, estimated to 8 months

Description: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)

Measure: Mental health - Depression

Time: through study completion, estimated to 8 months

Secondary Outcomes

Description: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)

Measure: Moral distress in healthcare workers

Time: through study completion, estimated to 8 months

Description: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)

Measure: Moral resilience in healthcare workers

Time: through study completion, estimated to 8 months

Description: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)

Measure: Social life

Time: through study completion, estimated to 8 months

Description: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)

Measure: COVID-9 symptoms

Time: through study completion, estimated to 8 months

Description: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Adverse health long-term outcome

Time: 5 years before the outbreak and two years after

Description: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - Inpatient

Time: 5 years before the outbreak and two years after

Description: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - ER

Time: 5 years before the outbreak and two years after

Description: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

Measure: Health care utilization - Outpatient

Time: 5 years before the outbreak and two years after

Description: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)

Measure: Sleep

Time: through study completion, estimated to 8 months
14 Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19

Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.

NCT04374110
Conditions
  1. COVID
  2. Hypertension
  3. Cardiovascular Diseases
  4. Cardiovascular Risk Factor
Interventions
  1. Other: Clinical data
MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension

Primary Outcomes

Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Measure: Adverse events

Time: through study completion, an average of 2 weeks

Secondary Outcomes

Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Time: through study completion, an average of 2 weeks

Description: Ventilation during hospitalization

Measure: Ventilation during hospitalization

Time: through study completion, an average of 2 weeks

Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Time: prolonged follow up, through study completion, an average of one year
15 A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer

The coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused considerable morbidity and mortality in over 170 countries. Increasing age and burden of cardiovascular comorbidities are associated with a worse prognosis among patients with COVID-19. In addition, serologic markers of more severe disease including coagulation abnormalities and thrombocytopenia, are not uncommon among patients hospitalized with severe COVID-19 infection and are more common in patients who died in-hospital. As the COVID-19 pandemic continues to grow, there is a pressing need to identify safe, effective, and widely available therapies that can be scaled and rapidly incorporated into clinical practice. Understanding the putative mechanism of increased mortality risk associated with abnormal coagulation function and cardiac injury is critical to guide studies of promising therapeutic interventions. Published and anecdotal reports indicate that endothelial dysfunction and thrombosis are common in critically ill patients with COVID-19, including reports of diffuse microvascular thrombosis in the lungs, heart, liver, and kidneys. Patients with cardiovascular disease (CVD) and CVD risk factors are known to have endothelial dysfunction and a heightened risk of thrombosis. A recent study of COVID-19 inpatients from Wuhan, China observed that an elevated D-dimer level greater than 1 ug/mL was associated with an 18 times higher risk of in-hospital death, underscoring the importance of increased coagulation activity as a potential modifiable risk marker that may drive end-organ injury. Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease, and the association between coagulopathy and adverse outcomes in patients with sepsis, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy and safety.

NCT04377997
Conditions
  1. Cardiovascular Diseases
  2. COVID-19
Interventions
  1. Drug: Enoxaparin
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Aim 1 - Risk of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

Measure: Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

Time: 12 weeks

Description: Aim 2 - Risk of major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

Measure: Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

Time: 12 weeks
16 COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry

Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease. Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry. Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.

NCT04390555
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
  3. Cardiovascular Risk Factor
  4. Heart Failure
MeSH:Heart Failure Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Congestive heart failure Left ventricular dysfunction Right ventricular failure

Primary Outcomes

Description: All-cause and cardiovascular mortality during index hospitalization.

Measure: In-hospital mortality.

Time: Hospitalization period, assessed up to 30 days

Secondary Outcomes

Description: The duration of hospitalization on the intensive care unit.

Measure: The length of stay in the intensive care unit.

Time: Hospitalization period in the ICU, assessed up to 30 days

Description: The total length of stay in the hospital.

Measure: The duration of hospitalization.

Time: Hospitalization period, assessed up to 30 days

Measure: The need and duration of invasive mechanical ventilation.

Time: Hospitalization period, assessed up to 30 days

Measure: Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.

Time: 3 months

Measure: Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.

Time: 6 months
17 Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial)

Most patients undergoing a cardiovascular procedure need an ICU-bed during the hospitalization and therefore it is possible that for the unforeseen future, because of the Covid-19 crisis, many patients will stay on the waiting list for many months to come. There are some studies showing an increased mortality associated with an increased waiting time for the patients on the waiting list for an elective cardiac surgery. However, there is no data on the evolution of the morbidity, the quality of life and the symptomatology of the patients waiting for an elective operation. Also it is not clear whether the period of waiting for an elective cardiovascular operation would impact the morbidity or the mortality of the planned operation at later stage. Furthermore, there is a plethora of studies on risk factors associated with the perioperative morbidity and mortality in general. Therefore, the rationale of the current study is to evaluate whether Digital Cardiac Counseling (DCC) would improve outcomes of the patients waiting for an elective cardiac operation. At the DCC platform, there will be assessments of cardiovascular symptoms, Covid-19 prevention for cardiovascular patients, smoking cessation, anxiety relief, exercise stimulation, pulmonary rehabilitation and diet adjustments. This will be done by means of questionnaires and E-consults.

NCT04393636
Conditions
  1. Cardiovascular Diseases
  2. Cardiovascular Risk Factor
Interventions
  1. Other: Digital cardiac Counseling
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention

Measure: MACEs

Time: Cumulative incidence (from inclusion) at 1 year postoperatively

Secondary Outcomes

Description: all-cause mortality

Measure: Mortality

Time: Before the scheduled date of the operation, at 30 days, in-hospital (at 30 days or during the same hospitalization for the planned procedure), at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

Description: Mortality caused by cardiovascular disease

Measure: Cardiovascular-related mortality

Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

Description: Mortality caused by Covid-19 infection and/or related complications

Measure: Covid-19 related mortality

Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

Description: Measured using SF (Short Form) 36 Health Survey

Measure: Health-related quality of life

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: New York Heart Association Functional Classification

Measure: NYHA Functional classification

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Grading of angina pectoris

Measure: CCS (Canadian Cardiovascular Society grading of angina pectoris)

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention

Measure: MACEs

Time: during waiting time measured before the scheduled date of the operation, at 1-year postoperatively

Description: Respiratory failure, pneumonia, septicemia, renal failure, myocardial infarction, stroke, atrial fibrillation, pacemaker implantation, re-operation, delirium, wound infection, urinary tract infection and pressure ulcers

Measure: Perioperative complications

Time: during waiting time measured before the scheduled date of the operation, at 30 days postoperatively and at 90 days postoperatively

Description: from surgery until discharge in days

Measure: Hospital length of stay

Time: from the admission to the hospital untill discharge from the hospital, assessed up to 12 months

Description: measured in hours from arrival in ICU until extubation

Measure: Time on mechanical ventilation

Time: from the admission to the ICU untill discharge from the ICU, assessed up to 12 months

Description: whether patient is active smoking

Measure: Smoking status

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Measured using HADS (Hospital Anxiety and Depression Scale) score

Measure: Anxiety and Depression

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: the percentage of patients taking part in postoperative cardiac rehabilitation

Measure: Participation in postoperative cardiac rehabilitation

Time: postoperatively at 3 months, at 6 months and at 12 months

Description: Percentage BMI<20 or BMI>30

Measure: Body-Mass Index (BMI)

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Unplanned visits to emergency department

Measure: Number of participants with unplanned visits

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

Description: Total costs of the whole treatment process

Measure: Healthcare costs

Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months
18 Association of Early Myocardial Injury With Major Adverse Outcomes in Patients With COVID-19

The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.

NCT04397939
Conditions
  1. COVID-19
  2. Myocardial Reperfusion Injury
  3. Cardiovascular Diseases
MeSH:Cardiovascular Diseases Reperfusion Injury Myocardial Reperfusion Injury Wounds and Injuries
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Number of death during hospitalization

Measure: Number of In-Hospital Death

Time: During hospitalization, average 2-3 weeks

Secondary Outcomes

Description: Length of stay in the hospital

Measure: Length of Stay

Time: During hospitalization, average 2-3 weeks

Description: Successful treatment will be defined by two consecutive negative tests for COVID-19

Measure: Number of Successful Treatment

Time: During hospitalization, average 2-3 weeks
19 STATIN THERAPY AND COVID-19 INFECTION (STACOV PROJECT)

Considering that simvastatin, and probably statins in general, interfere with SARS-cov-2 cellular uptake and some inflammatory pathways activated by the virus, those patients on statin therapy should be less vulnerable to infection and their clinical course and prognosis should be better than that in individuals not on statin therapy.

NCT04407273
Conditions
  1. COVID
  2. Statin
  3. Cardiovascular Diseases
Interventions
  1. Drug: observational
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Assess the difference in the WHO SARS-cov-2 scale of severity (9 steps) achieved by Covid-19 infected patients, admitted in the hospital, with and without background statin therapy comparable in age and gender distribution

Measure: SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy

Time: at the time of admission
20 Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury

Cardiac Troponin elevation is associated with adverse prognosis in COVID-19. The MIIC-MI study aims to investigate mechanisms of cardiac injury in COVID-19 using multi-modality imaging and immunophenotyping to better understand the link with adverse patient outcomes.

NCT04412369
Conditions
  1. COVID19
  2. Cardiovascular Diseases
Interventions
  1. Diagnostic Test: Non-invasive cardiac imaging
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Measure: Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.

Time: Baseline

Secondary Outcomes

Measure: Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging

Time: Baseline

Measure: Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging

Time: Baseline
21 Qatar Cardiovascular COVID-19 Registry

The novel coronavirus, severe acute respiratory syndrome coronavirus 2, that causes coronavirus disease 2019 (COVID -19), is highly contagious in the community and has resulted in a global pandemic. This infection has a special implication on the patient who complains from cardiac disease or acute cardiovascular condition and may result in cardiovascular complications such as myocardial infarction. For this end, we target to study this group of patient, who has a cardiac disease with COVID-19 in Qatar, in addition, the acute myocardial infarction with COVID-19 from the Gulf countries and collect all the related data to come with a comprehensive view about those patients.

NCT04430374
Conditions
  1. Cardiovascular Diseases
Interventions
  1. Other: No interverntion
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: The outcome of this registry will be: entire information about the patients who admitted with COVID-19 accompany with a cardiovascular condition in Qatar. Additionally, a comparison will be conducted between the cardiac patient who admitted over the period February to December to December 2020 and the same category of patients over the same period of 2019 in Qatar to figure out the reason behind the dropping of the number of the patient. A multicenter data from the Gulf countries for Acute MI patients infected with COVID-19. A comparison between our patients (either in Qatar only or the entire Gulf) populations and the outcome of other international registries such as the NACMI (US registry)

Measure: The impact of COVID-19 on cardiovascular patient

Time: 2 month from starting date
22 WHF COVID-19 and Cardiovascular Disease Survey

A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

NCT04475471
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure [including Left ventricular ejection fraction], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

Measure: Assessment of the patients for major adverse cardiovascular events (MACE)

Time: Outcome will be assessed at discharge and 30-day follow-up visit from the hospital admission date.

Description: Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

Measure: Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]

Time: at discharge and 30-day follow-up visits from the hospital admission date.

Description: Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

Measure: Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)

Time: at discharge and 30-day follow-up visits from the hospital admission date.

Description: Specific causes of death to be evaluated using CRF including sudden cardiac death, death due to Myocardial infarction, Death due to heart failure, death due to stroke

Measure: All cause deaths

Time: any time during the hospital admission and at 30-day follow-up.
23 Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients

Non-commercial depersonalized multi-centered registry study on analysis of chronic non-infectious diseases dynamics after SARS-CoV-2 infection in adults.

NCT04492384
Conditions
  1. Covid19
  2. SARS-CoV-2 Infection
  3. Pneumonia
  4. Copd
  5. CKD
  6. Cardiac Event
  7. Overweight and Obesity
  8. Cardiovascular Diseases
  9. Diabetes
  10. Hypertension
  11. Coronary Heart Disease
Interventions
  1. Other: non-interventional
MeSH:Infection Communicable Diseases Cardiovascular Diseases Heart Diseases Coronary Disease Overweight Noncommunicable Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: percentage of patients with non-infectious diseases relating to overall number of patients registered in study

Measure: rate of non-infectious diseases

Time: 12 month since a moment of request of medical help

Description: correlation between number of patients with COVID-19 of various severity and number of pre-existing conditions and their severity among these groups

Measure: severity of COVID-19 depending on pre-existing diseases

Time: 12 month since a moment of request of medical help

Description: Registration of disability or change of disability status

Measure: disability registration / change of disability status

Time: 12 month since a moment of request of medical help

Description: rate of deaths among registered participants

Measure: rate of letal outcomes

Time: 12 month since a moment of request of medical help

Description: correlation between number of deaths and pre-existing diseases

Measure: rate of letal outcomes depending on pre-existing disease

Time: 12 month since a moment of request of medical help
24 Development of a Dysphagia Risk Stratification Tool and Clinical Bedside Screening Tool in Cardiovascular Surgical Patients

The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing cardiovascular surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.

NCT04496986
Conditions
  1. Cardiovascular Diseases
Interventions
  1. Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
MeSH:Deglutition Disorders Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Dysphagia Oral-pharyngeal dysphagia

Primary Outcomes

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

Measure: Penetration Aspiration Scale

Time: Baseline (Prior to surgery)

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

Measure: Penetration Aspiration Scale

Time: Follow-up - Within 72 hours following extubation from surgery

Secondary Outcomes

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

Measure: Yale Residue Severity Rating Scale

Time: Baseline (Prior to surgery)

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

Measure: Yale Residue Severity Rating Scale

Time: Follow-up - Within 72 hours following extubation from surgery

Other Outcomes

Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

Measure: Vocal Fold Mobility Impairment

Time: Baseline (Prior to surgery)

Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

Measure: Vocal Fold Mobility Impairment

Time: Follow-up - Within 72 hours following extubation from surgery
25 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults in the Era of Coronavirus Disease 2019 (MITIGATE)

MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).

NCT04505098
Conditions
  1. Covid19
  2. Atherosclerosis
  3. Cardiovascular Diseases
  4. Upper Respiratory Tract Infections
Interventions
  1. Drug: Icosapent ethyl
MeSH:Respiratory Tract Infections Cardiovascular Diseases Atherosclerosis
HPO:Abnormality of the cardiovascular system Atherosclerosis Respiratory tract infection Type IV atherosclerotic lesion

Primary Outcomes

Description: Confirmed viral URIs (i.e., including recurrent events) (i.e., COVID-19, influenza, and other known viral respiratory pathogens) based on laboratory testing (i.e., FDA or locally-approved testing modalities) with an oxygen saturation <94% on room air and/or requiring any form of supplemental oxygen.

Measure: Percentage of patients with moderate or severe confirmed viral URIs

Time: 0-12 months

Description: At any point in time based on a 7-point ordinal scale (i.e., 1 = death, 2 = mechanically ventilated/extracorporeal membrane oxygenation, 3 = high flow supplemental oxygen, 4 = low flow supplemental oxygen, 5 = hospitalized with no supplemental oxygen requirements, 6 = urgent care or emergency department visit not leading to hospitalization, and 7 = no relevant clinical encounters)

Measure: Worst clinical status due to a confirmed viral URI

Time: 0-12 months

Other Outcomes

Measure: Percentage of participants who die due to any cause

Time: 0-12 months

Description: Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke

Measure: Percentage of participants experiencing a major adverse cardiovascular event

Time: 0-12 months

Description: Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)

Measure: Percentage of participants experiencing an expanded major adverse cardiovascular event

Time: 0-12 months

Measure: Percentage of participants who are hospitalized for heart failure

Time: 0-12 months

Measure: Percentage of participants who are hospitalized for any reason

Time: 0-12 months

Measure: Percentage of participants who have an emergency department visit for any reason

Time: 0-12 months
26 Investigating the Association Between Smoking Status and COVID-19 Outcomes: Collecting Data From Health Systems Affiliated With the National Cancer Institute's Cancer Center Cessation Initiative (C3I)

This cohort study will obtain electronic health record (EHR) de-identified data from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19 patients to explore whether smoking status, cancer history, and other risk factors among patients diagnosed with COVID-19 are associated with mortality and/or COVID-19 disease severity/complications. Each site will provide de-identified data from their health system EHR on a monthly basis that includes all patients identified as having COVID-19 at some point in the interval from February 1, 2020, through December 31, 2020.

NCT04506528
Conditions
  1. Covid19
  2. Cancer
  3. Nicotine Dependence
  4. Pulmonary Disease
  5. Cardiovascular Diseases
  6. Immunosuppression Disorders
MeSH:Cardiovascular Diseases Tobacco Use Disorder
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: Death resulting from COVID-19 illness in inpatients vs discharge from hospital (binary outcome)

Measure: Mortality due to COVID-19

Time: February 1, 2020, through December 31, 2020

Description: COVID-19 severity as measured by intubation for respiratory support (i.e., patient required intubation during hospitalization) - binary variable

Measure: COVID-19 Severity

Time: February 1, 2020, through December 31, 2020
27 A Survey to Assess Effects of the Covid-19 Pandemic on Symptomatology, Treatment and Medical Care for Cardiovascular Patients

The design included 152 patients with confirmed heart failure (HF) evaluated in two different periods of time: a baseline before the outbreak, and other during the outbreak of which 76 patients were randomized in each group. A care and follow-up guide was used as an instrument through a face-to-face survey (baseline group) and telemedicine (group outbreak). The primary outcome was the comparison of functional class modification observed in patients

NCT04508920
Conditions
  1. Cardiovascular Diseases
  2. Heart Failure
Interventions
  1. Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: NYHA class modification in the last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). NYHA Scale: Minimum: 1 to maximum :4

Measure: NYHA class deterioration

Time: 1 year

Secondary Outcomes

Description: physiological parameter to worsening of shortness of breath perception, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021).Dichotomic scale presence or absence

Measure: Dyspnea deterioration

Time: 1 year

Description: Physiological parameter to worsening of dyspnea that suddenly occurs to decubitus, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.

Measure: Paroxysmal nocturnal dyspnea deterioration

Time: 1 year

Description: Physiological parameter to worsening of quantification of swollen ankles in both pelvic limbs, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence

Measure: Edema

Time: 1 year

Description: a perceived limitation on walking more 500 meters, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.

Measure: Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration

Time: 1 year
28 Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial

Coronavirus disease (COVID-19) related pneumonia significantly impact patients with underlying cardiovascular (CV) conditions. Animal studies suggest that drugs commonly used to treated CV diseases may increase the ability of COVID-19 to infect cells. The RAAS-COVID-19 trial aims to assess whether temporarily holding these CV drugs in patients who are admitted with COVID-19, versus continuing them, in patients admitted with COVID-19 can impact short term outcomes.

NCT04508985
Conditions
  1. COVID-19
  2. Cardiovascular Diseases
Interventions
  1. Other: Temporarily holding the RAAS inhibitor [intervention]
  2. Other: RAAS inhibitor [continued standard of care]
MeSH:Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system

Primary Outcomes

Description: The primary end point is a global rank score which is applied to all participants. The global rank sum is based on the following endpoints (and corresponding score): Death (7); Transfer to ICU for Invasive ventilation (6); Transfer to ICU for other indication (5); Non-fatal MACE (Any of the following - MI, Stroke, Acute HF, new onset Afib) (4); Length of stay > 4 days (3); Development of acute kidney injury (>40% decline in eGFR or doubling of serum Cr) (2); Urgent intravenous treatment for high blood pressure/hypertensive crisis (2); >30% Increase in baseline high sensitivity troponin (1); >30% increase in baseline BNP (1); Increase in baseline CRP to 48 hours >30%(1); Lymphocyte count drop >30% (1). The primary endpoint will be assessed from baseline to day 7 (or day of discharge if occurs before day 7). Participants will receive a weighted score depending on the events experienced. The global rank sum score will then be averaged and compared between treatment arms.

Measure: Global rank score

Time: Baseline - day 7
29 Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff

Patients are part of a family network. When any person in a family becomes critically unwell and requires the assistance of an Intensive Care Unit (ICU), this has an impact on all members of that family. COVID-19 changed visiting for all patients in hospitals across Scotland. It is not known what effect these restrictions will have on patients' recovery, nor do we understand the impact it may have on their relatives or staff caring for them. This study will look at the implications of the visiting restrictions as a consequence of the COVID-19 pandemic upon patients without COVID-19 who are in the cardiothoracic ICU. It will also explore the impact of these restrictions on them, their relatives and staff. This study will be carried out within a single specialised intensive care unit in Scotland using mixed methods. The first arm of this study will use retrospective data that is routinely collected in normal clinical practice. The investigators will compare patient outcomes prior to COVID-19 with outcomes following the implementation of COVID-19 visiting restrictions. The aim is to establish if the restrictions on visiting has an impact on the duration of delirium. Delirium is an acute mental confusion and is associated with longer hospital stays and worse outcomes in this patient group. The second arm of this study involves semi-structured interviews with patients, relatives and staff that will allow deeper exploration of the issues around current visiting policy. The interviews will last approximately 1 hour and will address these issues. They will then be transcribed word for word and analysed using grounded theory, meaning the theories will develop from the data as it is analysed.

NCT04538469
Conditions
  1. Cardiovascular Diseases
  2. Delirium
  3. Critical Illness
  4. Intensive Care Unit Delirium
  5. Thoracic Diseases
  6. Respiratory Failure
  7. Cardiac Disease
  8. Cardiac Failure
Interventions
  1. Other: COVID visitation restrictions
MeSH:Respiratory Insufficiency Thoracic Diseases Delirium Cardiovascular Diseases Heart Diseases Heart Failure Critical Illness
HPO:Abnormality of the cardiovascular system Congestive heart failure Left ventricular dysfunction Right ventricular failure

Primary Outcomes

Description: Number of days patient found to have delirium using the Confusion Assessment Method for the ICU (CAM-ICU)

Measure: Duration of delirium

Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.

Secondary Outcomes

Description: CAM-ICU

Measure: Incidence of delirium

Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.

Description: Days

Measure: Length of critical care stay

Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

Description: Days

Measure: Length of hospital stay

Time: From the date of admission to the hospital until discharge from the hospital or death, whichever came first, up to 12 months.

Measure: Doses of specified drugs during ICU admission

Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

Description: Days

Measure: Length of time ventilated

Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

Measure: Mortality

Time: 6 months

Other Outcomes

Description: Semi structured interviews

Measure: Exploring the experiences of patients, relatives and staff of the visitation restrictions during the COVID-19 pandemic

Time: 18 months

HPO Nodes


HP:0001626: Abnormality of the cardiovascular system
Genes 4136
TWIST1 KRT14 ELMO2 SDCCAG8 KCNJ1 TCIRG1 MICOS13 MTAP RAG1 INSR ELP1 KCNAB2 TSFM HEPHL1 RNASEH2C CD19 EPCAM DNAH1 NF1 EYA4 SIX3 ASAH1 LORICRIN CTSB NDUFS7 GPR35 TMEM138 MFAP5 CYP11B2 GNA11 SHOC2 RDH12 HCCS SF3B4 GLA CC2D2A CCR1 PIEZO1 ATP8 TRNL1 CCR6 TTC7A PTCH1 DSP EPHB4 ANOS1 CALM1 B9D1 F5 ERCC3 MPIG6B TTPA FHL2 GBA CFI ALAS2 ATP6AP2 ROR2 COQ2 CLCNKB BSCL2 HPS4 SLC7A14 PIEZO2 IFT43 GBA BCL2 PHYH SLX4 INSR OCLN CHRNG ACADVL SARDH PAX8 TREX1 SFTPC NSMCE3 SLC19A2 SFTPB NFIX RPGRIP1 KRT5 IGFBP7 AQP2 AKT3 DYNC2I1 TRIP11 RPE65 KDM6B TNNT2 BRF1 NBAS RAI1 FOXF1 PHGDH FLRT3 F11 EVC2 WT1 COL5A2 ZFPM2 SDHA EBP CHCHD2 TNNI3 ATF6 UFD1 LETM1 NDUFAF3 DDC TDGF1 HTRA1 MEGF8 TMEM126B HNRNPA2B1 ACTC1 SDHD SEC61A1 ICOS ZFPM2 CD3D IRF5 GPC1 FOXJ1 FANCE CHRNG JAK2 PCCA GANAB PPP2R5D DNMT3A DCC POU3F4 ANKRD11 EXTL3 DEAF1 TAF1A MMP2 VWF PYGM HESX1 HLA-DRB1 ACTG2 MIB1 TWIST1 SMAD4 WNK4 PEX12 ERCC3 LBR ALPK3 SMAD4 MAFB C8ORF37 F2 ATP6V0A2 SOS2 LEP BRCA1 CEP41 GP1BA GJC2 FBN1 CERKL DOLK KCNE1 MSH6 CFHR1 CREBBP OTC OTUD6B POLG DNAI2 PLG SH2B3 PKD1 ACADM BCR MITF IGLL1 IRAK1 ND6 TERT NSD2 PPOX FBP1 LEPR PEX2 HMGCL ATXN7 RPS17 MYL4 FOXP3 SLC25A3 VPS13B PRPF4 NODAL FLT4 KCNA1 PEX13 SMARCE1 TTC8 NKX2-1 MTFMT MEOX1 NAA10 TGFBR2 NDUFB3 XYLT2 PBX1 CDKN1C MTTP CD244 PIGT PKD1L1 NDUFAF3 H19 LEMD3 ABL1 CFTR PYGL CYP1B1 CHRM3 LMNA CDC45 CCDC114 HGSNAT ADA HLA-DRB1 RAF1 DCHS1 TAPT1 NLRP3 DLL1 ND6 EVC2 RP1 RECQL4 POU1F1 CST3 CTSH SDHC ASAH1 SDHD NLRP12 ABCC9 SOX4 KCNJ2 XPC PRDM16 ACSL4 MNX1 MYO18B RTTN MCIDAS ABCC8 STXBP1 DTNA GDAP1 NPHP3 PIGM A2ML1 NUP188 POLA1 GUCA1B GUSB TRPC6 OTC ND3 COG7 PDCD10 C4A AVPR2 CD79B APOE AMER1 MYOT FZD2 PLOD1 HLCS MED12 PROP1 CANT1 MYF6 TNFRSF11A ARHGAP31 PRKCSH KCNH2 PDE3A ORAI1 KCNQ1 SMCHD1 PDE6B TMEM237 SDHC KCNQ1 TSC2 CFTR PEX7 C1QBP WWOX CFAP298 SCN2A NAGA CYB561 PRDM16 MMUT WNK1 ABCG8 ALG12 GLI3 HGD NDUFS1 CALM1 BLM TBX5 GALNS COL4A3 SOX10 ZBTB16 CYTB ANTXR2 NAGLU PPA2 TMTC3 SDHA DYNC2I1 FLT1 FLT4 HCRT CCDC39 ARMC4 HLA-B ABCA3 BCOR POR COL1A1 APP FAS TPI1 MBTPS2 NEU1 APOA5 MMP21 PRG4 JAG1 LRP2 MYH7 FLNA F13A1 PTPN22 TWNK KRT14 KYNU COG2 NAA10 MYL3 CENPF RYR1 FLNC VPS35 SOX2 TRAF7 GATA4 SDHA ATP7A ZDHHC9 TREX1 KCTD1 TRIM28 POLH CYP7B1 PIK3CA BBS12 SLC12A3 MVK MYOT GFI1 CYP11B2 TAZ TACO1 TET3 IGH ATN1 COL4A4 KIAA0586 WT1 RRM2B PSMB9 C3 MAPT TRNS1 NFKB1 HFE GBA BMPR1A ERCC3 TET2 HLA-DRB1 MFAP5 EPG5 KYNU PIK3R2 HADHB APC XIAP CLCNKB BRAT1 CDC73 MS4A1 BRAF FAM111A NAGA TET2 FMR1 APP ND2 MIF SCN5A STAT4 GFI1B BBS7 CDK13 UQCRFS1 GJB2 TPM2 HRAS UROS SNAP29 ADAMTSL4 RAD51C GNPTAB SDHB HBA2 CDC42 TRNL1 IDUA TBX1 POLE CD96 CALR LMNA GMPPB DPH1 OFD1 OTUD6B ITGA2B CAV3 LZTR1 TRAIP GGCX IL2RG DCTN1 CYLD ENG DSG4 CACNA1C POGZ PHKG2 PDE11A TFAP2B ND4 FAM161A MGAT2 WDR19 PARN IDH2 ASXL2 SMAD4 NR3C2 USP45 PRKAR1A KDSR GPI FBN1 VCP HELLPAR FASLG NR0B1 ABCC9 DMRT3 FOXRED1 HOXA11 KRT1 CDK10 POLG MERTK RPGR HBB CFHR1 SCNN1G ETHE1 CBS HLA-DRB1 TRNV PSAP TGFBR1 SLC25A26 NDUFB11 AHI1 CD46 RRAS IARS2 KIF7 MAT2A IFT172 CALM2 ATP2C1 GALE CCN2 WNT10A TBX3 RPS6KA3 B4GALT7 POMT2 OSGEP ROBO4 RSPH1 TMEM231 LIMK1 PDE6H LBR MINPP1 MRAS PRRX1 PSEN1 LMNA JAK2 HLA-DRB1 AFF4 PDE6A NOTCH3 DNM2 CNGA3 ELN NDUFS8 CTSK COL1A2 LMNA GBE1 RRM2B ATP6 POLR1A GNAQ SYNE2 ADA2 CACNA1C EPB41 HSD3B2 NRAS DNAH9 FAM13A SALL4 HADH DNM2 CHRNA7 NSDHL XPC DMD NDUFV2 GATA1 SHOC2 AGK TNFSF11 ROR2 HMGA2 LRP6 TNFRSF13B TRNQ PROS1 CDKN2A POLR1D COX3 XYLT2 MYH11 COQ2 AGK GATA4 TNNT2 MTOR SRCAP MYMK B2M DOCK6 LRP2 MYSM1 MGMT CTCF AGL TOP3A F2 NDUFB10 FRAS1 SCNN1A IRF5 ABCC9 SDHD NRAS SOX2 TECRL SKI NBEAL2 GP1BB CORIN ZNF365 C1R PRKAR1A CTSA H19-ICR B9D1 LAMA2 EXT1 INPPL1 AGT XPR1 UNG SLC25A4 NKX2-5 DST FIBP PIK3CA DNAAF6 LMNA SCN10A FOS CCDC141 CPLANE1 CCDC141 JPH2 HFE KAT6A VEGFC JAK2 STAMBP FGFR2 LEMD3 TMEM216 PPA2 CLN3 LMX1B TRNS1 ANK1 LMNA SDHC PEX11B MED12 PCCB TMEM237 ALG10B IL12A PRF1 KCNJ2 FLNB FCGR2B RHO HAND2 KCNQ2 KIZ CLCN7 CC2D2A SMAD3 IDUA ABCC8 ADA2 DSP TMEM43 BBS9 NABP1 NLRP1 TCIRG1 SKIV2L HCN4 FERMT3 ENPP1 MTM1 LZTFL1 WNT10A MGME1 TNNC1 DNAJB11 CHKB BRCA2 NELFA NT5E COX1 TBL1XR1 GJB4 CCND1 NR2F2 TRRAP ZFPM2 RPGRIP1L PROM1 RYR1 PYCR1 RYR1 DNAI1 DNAH1 DPM1 CYBB ND6 SNAI2 TARS1 ALMS1 ELN HJV PNPLA6 DMD KCNE1 F10 RAG2 TERT STX16 COL5A1 FGB NUP107 KIT GATA6 PLP1 ATP6V1E1 CA4 LHX4 DPP6 STRA6 PIEZO1 FBN1 PSMB4 PCARE LRRC6 ABCC6 SUFU COX2 DNAAF5 WNT4 RET STOX1 SCNN1A IRF5 LTBP2 TFAP2B USP9X INTU HDAC4 SPECC1L CTNS MGME1 TTC8 FAS CYP11B1 SLC2A1 CPLANE1 CCDC151 SPAG1 GDF1 PEX2 TERT NPHP1 PRKAG2 DPP9 AARS2 AMER1 LIFR KCNE2 NFKBIL1 SDHB SCO1 NDUFAF6 ARID1A RPS24 PGM1 GATA5 KAT6B NOP10 FGFR1 IFT80 SEC63 COL1A1 RBM8A MYMK MAP3K1 SLURP1 TAZ TBX1 SRCAP CPT2 CTNNB1 TCAP HBB KRAS COX7B SAMD9 GATA6 COG4 PML SLC29A3 SERPING1 GP1BA ARX DDB2 COG8 TOPORS WDR11 SCNN1B ADAM17 KIT GATA6 CENPE DNAAF5 NPPA ND4 RPL26 CSPP1 SLC25A20 GNAQ KLHL41 SCARF2 ECE1 SEMA3E ANTXR1 AKR1D1 CHD7 CC2D2A VCL ADAMTS2 GPR101 FLNA FERMT1 ATOH7 MAN2B1 LMX1B RAB3GAP2 ATRX CEP290 MYORG BCL6 TP63 MCM4 FANCG TRAC FUZ HDAC8 ZNF469 ASXL1 STAT3 IL7R KATNIP ITGA2B FBN1 ANK1 FCGR2C COQ7 COQ2 NLRP3 HTRA1 TAZ ALDOB NDUFAF5 LETM1 DHODH AVPR2 RPL27 FANCI APC2 PIGA FBLN5 ACP5 SLC39A13 NRAS MYH7 PNPLA2 NUP155 RPS15A PTGIS CRPPA CDH23 EBP GTPBP3 KRIT1 FOXE3 EWSR1 SNX10 APOB RPGRIP1L ASXL1 SF3B4 PKD2 FBP1 SMO ANK2 NOTCH1 ABCC6 THOC6 PRCD NDP TRAF3IP2 FAN1 BMPR1A VPS33A NOTCH2 ERCC5 EFTUD2 CHST3 DYSF ALOXE3 ENG GANAB TTR INPP5E CD247 PRKAR1A EMD LIPT1 CACNA1S ANKS6 WAS CASP10 PIGT SAMD9 KCNN3 CA2 ATP7B PDE4D FBN2 POGZ ANTXR1 SLC26A2 GJA5 FGG RNF168 RP9 PTF1A KCNH2 BMPR1A POU2AF1 EHMT1 COX4I2 MPL DNMT3A ARMC5 MYPN DNAH5 RPL10 KRT1 EPHB2 INVS PQBP1 ACTC1 NKX2-5 FRG1 TECRL HEXB LMNA KLF1 RARB CEP290 GRIP1 GLI2 FOXA2 GYG1 TMEM127 CD79B KAT6B TBXA2R KDSR CALM1 HCN4 ADA2 PIK3CA IDH1 KRAS CACNA1H IRF8 ND5 KRAS COL6A1 NDUFAF1 NDUFS3 COL11A1 FBXL4 SMARCE1 COL5A1 PRPH2 TRIO MAP2K2 PEPD RPL35 DNAAF2 SLC25A3 ARF1 SEMA4A AP1S1 TGDS CD70 LMNB1 MAX TULP1 SNRNP200 FHL1 TNFSF12 CDSN ACTA1 GMPPA USP9X BBIP1 HLA-DQB1 NHP2 ANGPTL6 FBLN5 CWC27 PEX16 NDE1 SLC22A4 CHD7 HPGD GATA6 TKT PTEN TET2 BTD EVC BCHE TALDO1 FLNB EED ALDOA JAM2 CFAP53 USP8 PGM3 FGFR1 AP3B1 FLNA JAK2 SOX18 STIM1 PDGFRB KMT2D POLR1A GLI3 GLB1 GDF2 NEB IFT172 TSC2 CDIN1 TNNT2 NEK9 F7 KRAS BLNK GBA WDPCP CSRP3 REEP6 LMNA KCNN4 TNNI3 TP63 KIAA1549 RRAS2 MEFV ACTA2 KCNH2 TERT SACS RPL5 BRIP1 RUNX1 DDX11 KRAS TPI1 MED25 SALL4 ATM EYS KCNH1 GPR101 IGH DOLK BANF1 PEX1 GATA4 REN DHPS ND4 GPC3 MLH3 FAH RNF213 PRKG1 EXT1 RAF1 TRDN KCNQ1 CFH COL3A1 COLQ PAFAH1B1 GJA1 COL11A2 RUNX1 BCOR SDHB ALB CFI SLC7A7 TBX1 RNF113A RAI1 SLC37A4 TF PTCH1 RPGRIP1 CEP120 DLD RLBP1 PDSS2 CKAP2L EDNRA KCNH1 GALNT3 PCCA PALB2 MAP3K7 NFIX WT1 TAB2 SMARCB1 COX8A PAX3 THPO NRAS STX11 AGA RAD21 TBX19 F12 KCND3 MNX1 CEP290 ERCC2 GREB1L CD40 BEST1 CYTB TPM2 TRPM4 SLC25A20 MYOC MYH9 CLCN7 RET MST1 PEX12 DSE NDUFS6 ARSB TCTN1 NDUFA11 GJB6 SCNN1A KISS1R TERF2IP MPLKIP GPD1L OFD1 PDGFRB HYMAI ALKBH8 DNAAF4 LDB3 FGFR2 LRP5 GATA4 UNC13D MEOX1 ARL13B CYP3A5 ERCC2 WNT5A AGPAT2 TINF2 RHAG HSD3B7 GNE ATP11A NPHP1 ABCA1 PMM2 CEP104 GNAS ARL6 GTF2IRD1 TPM1 SDHD FANCB CDHR1 NF2 RAD21 NPC1 GPIHBP1 COL18A1 CEP57 CNGA1 TBX1 FGA LDLR POLG SMO NF2 SELENOI CPT1A CTLA4 ZMPSTE24 DPF2 C12ORF57 DIS3L2 SUMF1 OFD1 CD3E POMGNT1 NEK2 NEBL CAV1 ACTC1 MAK GCK COG6 BBS2 COMT XYLT1 SLC4A1 PEX5 DPM3 GP1BA RMRP RSPH9 GLIS3 SCN5A ERF DCDC2 RAB27A TP63 ERAP1 SOX5 TAF2 AIPL1 PEX19 TGFBR2 TNFRSF4 MYOC IL6 SRY PTDSS1 PDE6C PMS1 RAC1 TMEM94 ELN VWF MMP1 SEC23B CIITA RPL35A TEK CHRM3 LCAT ALX4 PRKAR1A MDH2 GSN G6PD CNGB3 GATA5 CYTB POLG FGG SCN4B MKS1 TTC8 IL2RB LMNB1 CAT SIX6 PARN IQCB1 TRPV3 MEFV GATA4 SH3PXD2B SDHB PACS1 NDUFA10 BCS1L PLAGL1 PRKCD SLC4A1 TALDO1 TUB ERCC6 ABCA1 BTK MYPN ELOVL4 NR2F2 HK1 SLC12A1 STRA6 RPL35A HBB RPS20 KMT2A AGA RPS26 ACTG2 KRT5 NCF1 MYC RAB23 ACTN2 MKS1 COL1A2 ARID2 NFKB2 ND2 ALX1 LRRC56 MTHFR EIF4G1 F13B SOS1 ACTC1 SGO1 CTC1 IFT122 FGFR2 CDKN2B SMAD3 HDAC8 MTO1 THOC6 SCNN1B HAVCR2 HBA2 UVSSA DNAAF6 CCDC8 FGA DHCR7 GLUL TREX1 GPC4 IL17RC TSC1 CITED2 CCM2 TCTN3 XRCC2 SERPINC1 RECQL4 PEX16 BEST1 SETBP1 MYBPC3 CASR KRAS SMAD6 TFAP2A NDUFA13 SLCO2A1 PTEN TDP2 RPS26 GFI1B KRT14 COX7B GYS1 SLC18A2 GNA14 PRF1 DSP COX3 PIK3CA RPS29 ND1 SCNN1A KCNJ18 CD40LG ARFGEF2 GATAD1 LOXL1 GP9 RSPRY1 F5 LRIG2 TRIM37 PSAP HLA-DRB1 FOXE1 F8 JUP FOXE3 TNNC1 NKAP SEMA5A RANGRF CASQ2 GBA GJB2 SMAD4 TNNI3 MAP3K7 AQP5 LMNA ABCA1 RB1 KCNJ11 ANK1 CRELD1 TGFBR2 MYH8 H19 ALOXE3 GPD1 EED PEX6 SOX18 FXN SMPD1 CALM3 MYH7 COL6A2 NF1 PTPRC SDHAF1 IKBKG CYP11A1 BIN1 MC4R ABCB4 DVL3 PLCG2 DMPK HEXA POLG2 ABCD3 TRNS2 PAFAH1B1 KRT8 NDUFS4 DNAH11 DCLRE1C POT1 PIGO SMOC1 APRT CDKN1A SDHD ARX ITGB3 FGG CAVIN1 FLNA CUL3 TMEM126A LDB3 SFTPA2 TTN PLCB4 HPGD SLC25A4 RIT1 PCNT DNAH5 CEP41 ZNF423 NONO RGR PQBP1 MAP2K1 YWHAE CCDC151 PTEN SCN1B MEN1 HYLS1 SCN3B KCNE5 TPM3 SLC35A1 TACR3 IGBP1 CHST3 IL12B SPEG SLC30A10 XPNPEP2 RYR2 ATM NDUFA6 IFT81 SURF1 SEC23B KLHL7 MEFV NBEAL2 SLC52A2 GATA4 DPH1 RPS17 EPHB4 KAT6B CEP164 PUF60 BTNL2 SMARCB1 SLC25A24 TNNI3K CTNND2 BRAF PGM3 DUSP6 ERCC2 PLD1 PDHA1 SMAD9 TBC1D24 CHD7 BBS1 ALG9 GJA1 CD28 MAP3K7 CCDC40 PNKP POR JAK2 GLI3 EXT2 CCN2 GPX4 EOGT ARL6IP6 AMMECR1 HOXA1 HIC1 FOXF1 NPHP1 GP1BB AHCY VCL TRNK EPHB4 GABRD PIEZO1 COLGALT1 SMN1 RSPH3 PRPH2 APP COG4 SMARCA4 GJA1 ITK KIF20A APOA1 HYDIN RET NOTCH3 RHOH JUP CASQ2 ANK2 CCR6 IFIH1 PLEC SNRPB HYLS1 C8ORF37 PRKCD SETD2 TGFB1 SCN1B GNAS GUCY1A1 IDUA CRB1 IL7 DNAH11 CCDC47 SPAG1 GJA5 PDX1 CPT2 TNFSF4 FBN1 FGF20 SH2B3 IL36RN STAT5B WRN COG7 APOA1 ARID1B SPTB FOXH1 NXN PRKAR1A ERBB3 GMPPB ECHS1 PNP ATP6V1B2 ZAP70 WRAP53 SMC1A STAT3 DNAAF1 FGF8 BMP2 LIMS2 F10 CP ITGB3 DBH LRBA TRNK GNB5 SOX11 F7 KLRC4 ATP5F1A NDUFAF2 PIEZO2 CRB2 AGXT NDUFB11 HSD17B10 WDR26 TNNI3 PRNP PALLD HLA-B PLCG2 NOD2 CTLA4 COL1A1 B3GALT6 MGP FGD1 HSD3B7 GBE1 CALM3 DNAAF4 NF1 MAN2B1 GPC4 TIMMDC1 NDUFAF8 RAD21 SNTA1 TMEM70 STRADA PRDM6 KDR DES MCTP2 PIGN AKAP9 EMG1 COG1 TFRC INPP5E HBA1 RPL11 KRAS PTPN11 SKI RBP3 HABP2 LAMP2 VPS33B ZNF513 FOXRED1 CCM2 SCN5A MKKS LDLRAP1 GALC SEMA3A TRNQ B3GLCT EXT2 RBM20 CCDC103 CLCN7 GNPTAB GBA EDA UBE2T AHI1 BNC2 SLC25A4 F13A1 COQ9 ATP8B1 APOE SMC1A PEX1 EDN1 PPARG CDKN2C ENPP1 GATA5 LRP5 SLC19A3 DLEC1 CCND2 EFEMP2 SGCB PEX5 CAV1 RBM10 TBX1 SPIB RFC2 NLRC4 SDHAF1 MCCC1 IL2RG SRP54 RAF1 GGCX TSC1 CCNQ LTBP3 GATAD1 SCN5A DVL1 NEB PTPN11 KRT9 CSTA FGFR1 CIB1 SCNN1G BBS2 DSE LRRC56 COA5 XK CASR DNAL1 MYCN SCN5A GATA4 TMEM70 ARPC1B LRP5 RPS7 HBB JUP TRNS2 TNFRSF13C SPTB UCP2 DVL3 NEK9 JAK3 MYPN IDS NDP DSC2 ND5 NFIA CITED2 MSX2 RYR1 SERPINF2 VWF CACNA1D EPG5 EHMT1 TCIRG1 CLRN1 CR2 POMT2 ELP1 B3GAT3 PADI4 TAB2 ACTA1 MKKS SMPD1 TSC2 MVK PLEKHM1 RNU4ATAC SELENON LTBP4 DDRGK1 BRAF AIP POLR3A ABCC9 FZD4 NR2E3 PTCH2 CCBE1 DCLRE1C PPP1R15B GBA MYLK TET2 TRPS1 ALDH3A2 ASCC1 PIGS TNXB ADCY5 CPOX CSRP3 SGCD GNAQ BSCL2 PPARG NEUROD2 PDSS1 FN1 FLT4 ABL1 NDUFA9 SPRY4 MAP2K1 LAMB2 CNGA1 TRMT10C DNAAF3 FLNC TNFRSF1B POMT1 GPC3 PGAP2 ND6 KCNJ8 TNFRSF1B TTC8 FANCE JAK2 GATA1 FGFR1 FKTN CHST14 PDGFB RFWD3 ELAC2 CPS1 COL4A1 RPSA TGFBR3 TGFB2 CACNB2 TTC25 SURF1 WIPI2 CDON PROP1 CHD4 GJA5 ACE HADH IGSF3 COQ2 GNS NPHP1 HPS5 NT5E APOB SDHD SMARCA2 GDF3 ABCB11 PSEN2 SPEG FH ADNP EXOC6B LONP1 SAMHD1 YY1AP1 PEX26 NOS1AP CALM1 SEC23B BRCA2 SLC26A2 JAK3 FIG4 SGCD GTF2E2 CASK CIZ1 XPNPEP3 HBA1 ZNF687 CARD9 FRA16E TF PSEN1 PKP2 C1S TRNV CYP11A1 KRAS MLXIPL RNASEH1 PRRX1 GNAI3 UBAC2 DNAI2 APOE HES7 ABCC9 MYH7 MYH6 TMC8 PCNA MED13L OBSL1 NAA10 NDP RORC CHN1 NSMCE2 VHL ATP6AP1 UBE3A CSF2RA SMARCA4 AK2 FIP1L1 FGB SAG PEX2 TGFBR1 LRRC8A SHPK DSG2 PLOD3 TLR4 HPS6 RMND1 ADA CFAP300 CYP21A2 NKX2-6 COA6 SLC4A1 COPA RHAG RPS15A GATA1 LPL SC5D SDHA RBCK1 RS1 GDF2 PAM16 DHX38 FLNA PTEN APP KBTBD13 IL10 SHH COG5 NPM1 SLC37A4 ND1 SAMHD1 RPL18 PTCH1 BRAF INHBA IGF2 CYP26C1 CDC42 ERCC6 VPS13A MPL RIN2 WT1 VPS13B GLI1 DUX4 FGG COL5A1 TTC12 CACNA1D TRDN CYBA TRNW ABCG5 FBN1 ARCN1 AFF4 FN1 ADAMTSL1 GATA2 TERC NSD1 KRT83 FN1 PROS1 NKX2-6 LONP1 NCF2 SMAD3 MARS2 NDUFS4 ITGB3 DLL4 DNAJC19 PLN PDE6G ROM1 SIK1 TBL2 OTX2 RNF135 RYR1 KYNU RBM8A CDKN1B TERC DSP GATA4 SCN4B DRC1 TCF3 TNFRSF1A IL1RN TULP1 TRNS1 GATA3 AIP SCN2B KCNJ5 GATA6 FBN1 GNAT2 IMPG2 SUFU CCDC114 BLOC1S3 CD55 HYMAI SMAD4 PHOX2B USB1 ZMPSTE24 ACAD8 TBXAS1 KDM6A MYH6 GLB1 SPATA5 SCNN1G VHL F13B GUSB COL3A1 CD96 PEX1 BAP1 SLMAP SMARCAL1 CTBP1 DSG1 FRG1 IL17F AMMECR1 FKRP ARHGAP31 TCOF1 MVK COX1 CLCN2 SCN5A XPA FGFR3 PTH1R AICDA UPF3B CASP10 KCNJ11 CC2D2A ECHS1 ERGIC1 CACNB2 NDUFAF1 NDUFV2 MYLK MYLK DYNC2LI1 RAG2 PKP1 STAT3 NSD1 DMD WDR35 LAT BGN TMEM43 NDUFS3 BPTF SEC23A CCDC174 CALR ICOS MYBPC3 CEP57 MRPS16 TRNT XRCC4 KIT ESS2 GNAS BCOR SUGCT ABCA4 BBS2 ESCO2 TCTN2 MRAS GP1BA MYH7 ELN CASK FSCN2 GLB1 CSF2RB SELENON BCOR ND4 KMT2D BBS4 ABCG8 HGSNAT COL2A1 BUB3 PDE8B LIPA SLC26A2 ARL3 FCGR2A FOXC2 F13A1 ATP5F1D GLA FANCI FGFR1 LYST NDUFV1 EDNRB SLC25A11 ARSA TEK ITCH WNT4 MPL SFTPA2 MMP1 IGHM SOX9 FGF8 SALL4 LZTFL1 SRD5A3 PKP2 DSP LTBP4 ACTA2 COL6A3 LEMD3 KIAA0586 MYOZ2 CTC1 SH3PXD2B NDUFS2 SH2B1 C2 LPIN2 KITLG PIK3R1 FLT4 WIPF1 DLST CASQ2 COX6B1 WDPCP HBB RAF1 LRRK2 FGFR2 COX14 TRNW EP300 FGB LFNG DNAL1 BAP1 CAPN5 ITPA SIN3A COL4A3 WDPCP HESX1 FKTN KIT PIGP WAS ZFP57 FGFR2 IL23R ATP6 DIS3L2 EFTUD2 DCHS1 FOXP1 ITGA3 CACNA1S CALR NDUFV1 CFH PEX5 USP8 DMPK CAP2 BTD ADAR BCR IL10 IFIH1 SOX10 CCDC40 GNB3 MRPL3 ERCC2 TPK1 CTSA PRKAR1A STK11 SMCHD1 HBB FKTN MEN1 ATRX TPM3 SCN1B AKT1 RRM2B KDSR DNMT3A ADAMTS10 PIK3CA CHRNA7 ND4L BMPR1A MAD2L2 ZMPSTE24 KCNH2 MED12 RP1L1 PPP2R1A APC IL12RB1 LARS2 TRNL1 POMT1 GJA8 RAF1 TANGO2 DYNC2H1 DGCR2 ALPL KIAA1109 NEK1 NODAL CAV1 PRKACA PCARE PTEN ERMARD RFWD3 PIGN KCNQ1OT1 AK2 RPL10 COL5A2 BLM KCND3 FGA RPL31 RIT1 RPL15 SLC4A1 JAG1 ACAD9 TUBB FTL TNFRSF11A PTPN22 ERCC4 PDGFB GDF1 GP6 PRKCD KIF1B ARHGEF18 TGFB3 TNNI3 PALB2 NDUFS7 PDE6D GJB3 KIT PRDM5 VHL TUBB NLRP3 SDHB STRADA PMS2 GPC6 ABCC6 TACO1 SMARCD1 SDHB HES7 TGFB3 TFAP2B TRNF RPS6KA3 IFNGR1 ALMS1 PDE6G CCDC28B PIGL CPT2 VHL FGFR3 PRDM16 PIGT MRPS22 HSPG2 MANBA TBCK HYOU1 CALR OFD1 UROS DCAF8 GDNF COG4 RREB1 HOXA13 TPM1 RUNX1 SELENON NPHP3 LBR PAH ALOX5AP WASHC5 AKR1D1 SMPD1 RFT1 PEX3 TMEM216 FAT4 RPS10 EOGT PITX2 TMCO1 HLA-DRB1 DES MEN1 ACTB KRT5 USP18 HTRA2 PEX19 ITGA2 SPATA7 NXN NID1 LMOD1 MKS1 LOX FBLN5 GATA4 COA8 MAN2B1 RASGRP1 SRY KCNJ11 KRAS SMARCB1 RECQL4 TRDN SP110 TAB2 NKX2-5 WT1 PSMD12 ACADL SLFN14 DISP1 AEBP1 SNTA1 DNAI1 SEMA4A ATP6V0A2 ACVR2B BCL11B FLAD1 RTEL1 ASCL1 CALCRL PIK3CA ATIC CCBE1 ASXL1 CDC73 SAMD9L WT1 MKS1 WDPCP F8 TBX4 UBR1 GBA SMAD4 GP1BB NEDD4L SBDS MIPEP ICOS RAD51 SLC26A2 ANO5 PEX11B BSCL2 PCNT KCNE3 EYS COL3A1 TERT SLC17A5 ADAT3 LIG4 IDUA IFT27 TWIST1 RAG2 EXT2 SMC3 HRAS MAP2K2 NDUFV2 PSEN2 ESCO2 LOX CRKL CDK4 RAG1 ITGB3 SPARC PALB2 GJA1 STXBP2 TGFB3 CBS PIGO TCOF1 TBX22 COL4A1 RLIM ADAMTS3 APC PIGL TPM3 CDH23 SCN9A NDUFS4 FOXC2 LMNA ENG SH2D1A SOX9 GATA1 TTN TMEM67 GLMN MPL LRRC6 USH2A IL12A MLH1 RP2 RPGRIP1L SETD5 IL7R MYL2 CCDC22 IFT172 IGH TKT NEXN KIF11 WNT5A ATP2C1 RPE65 PPP2CA SGCG CNTNAP2 SLC20A2 NKX2-5 PEX10 PIK3CD DHCR24 PIGW TTC25 SERPINF2 KRT18 MTFMT AKT2 HSD11B2 NDUFB9 GP1BB PHKA2 ITGA8 RNASEH2A ZNF513 TGM5 PERP PDE11A CLCN7 SMARCE1 SCNN1G CACNA1D WDR19 SLC4A1 NDUFB11 RAI1 LACC1 GM2A CYP11B1 RPL11 TNFSF15 MAB21L1 CITED2 FLNA FAT4 ANTXR1 KDM6A CLIC2 CFHR3 NUBPL SNX14 PIGY NDUFS1 LIPT1 SOX3 PSAP CPOX ND1 CD79A SLC22A5 LYZ PRPF6 FGFR2 MAPRE2 AMMECR1 LIG4 ARL6 CYSLTR2 PRPH2 CEP55 ELANE TRNC CLIC2 TSC1 FGFRL1 FUT8 ALDH18A1 DTNBP1 HABP2 TBX1 CHST3 SAA1 ATR BTK ZNF408 RSPH4A KANSL1 ERCC8 PHKG2 FHL1 PSTPIP1 HRAS CCDC65 TP53 NLRP3 NDUFS2 SPECC1L IGF2 CACNA1C GJA1 SH2B3 SYNE1 ITGA8 CYBC1 IRF8 CST3 CA2 GNAQ SCN10A MYD88 LMAN1 KRT16 VCL OTX2 SIX3 PIK3CA LMNA PLAGL1 HAVCR2 LMNA CYP11B2 MLYCD PITX2 AGGF1 AKT3 RPGRIP1L NOD2 NUMA1 DLL4 RERE MAPK1 MASP1 SPINK5 TMPO CTU2 AGTR1 TNNC1 TGFB1 CNGB1 XIAP SELENON UBR1 TRIM28 IFT140 TSPYL1 PTPN22 C2CD3 FAS RAI1 SPP1 TNFRSF11B ARMC5 PLEC IGF2 DCAF17 HLA-DPB1 PPARG PRKAG2 GLRX5 ARX SOS2 TWNK CCDC103 TRNH XYLT2 NAGS PIGV HGD RPL10 PEX14 GNA11 MYLK2 ERCC4 DMXL2 ADAMTS10 FBN1 ACTA1 CTSB REST CAV3 PEX12 FOXC1 GATA6 CAV1 CRYAB IRF8 BBS10 SRP54 DHCR24 STEAP3 ACD STN1 GCDH NDUFA12 MYH6 NSD2 BVES CD2AP LMNA SCN5A HPSE2 SCN4A POMK ALG1 CACNA1C FLNC FUCA1 COA3 G6PC HESX1 CFI RPS27 FGB ARL6 P2RY12 ABCA4 SCYL1 UMPS CAV3 LAMC2 STXBP1 SYT1 NMNAT1 TBX1 GGCX NSUN2 GJB3 RAD51C LMNA ITCH BAP1 BRCA1 ATP7A MYH6 LMNA PRTN3 NR3C2 CSPP1 WDR35 CCDC115 ZNF469 ZEB2 IDUA IMPDH1 HOXD13 TCTN2 SLC35A1 HMCN1 GAA FECH KRT10 PRCD BMP2 COX15 FGFR2 PLVAP SON RYR1 LIPC SLC25A24 FKBP14 RET AHCY KDM6A FAT4 COX15 LCAT KCNQ1OT1 RNF6 FGF17 SP7 CFAP410 NDUFA10 ACAD8 PIK3C2A NTRK1 CAV1 RNASEH2C IL17RA CDKL5 BEST1 TTN NSD1 ERCC2 EFEMP2 ABCB6 MMEL1 BUB1 ARL6 TKFC COX20 MYH7 CDKN2B UMPS GJB4 INTU CCDC22 DOLK TPM2 DSG2 H19-ICR HAMP WAS DOCK6 MYH6 HSD11B2 DNAAF1 SON AHR COL7A1 FLT4 RAG1 FKRP BRAF RASA1 PDE3A GBA KCNE1 CBL TNNT2 TRIP4 ADCY5 PHGDH PPP1CB HNRNPA1 SPTB G6PC3 RANBP2 LAMA4 CYTB MPI GDF6 SCNN1A CD19 TREX1 SCN10A KCNMB1 TOP3A SLC39A4 WWOX HADHA IGHM MYH11 TBX5 PET100 COL1A1 NAGA PTEN ABCA1 GNE GLI3 TXNRD2 TNFRSF11A NKX2-5 PDCD10 HSPG2 FBLN5 SCNN1B MYPN PROS1 SCAPER NPPA SCN1B CD19 FKBP14 WARS2 TTN ZNF148 ARL2BP FRAS1 HIBCH SDHC FANCF NECTIN1 PEX6 TBX3 TGFB2 MESP2 COX3 DOCK8 HYLS1 NRAS SCN3B ZIC2 MYO5B KAT6A MECP2 RSPO2 SGCB SPEF2 CCND1 NIPBL CALM2 F5 YY1 SLC2A10 KIF1B AIP ALDH18A1 INS TNFRSF1A MBTPS2 HBG2 TWNK ABCC8 RPL15 TRAF7 PIGN FGFR1 TBX20 KCNJ2 ZAP70 SFTPA1 SPTA1 ACTA1 EPAS1 SPECC1L TFR2 DSG2 ANO10 RTEL1 PROKR2 ABCA12 CBL HACD1 TRIM8 POMT2 TNPO3 TXNRD2 SLC29A3 TRNN ACAD9 ADAMTSL2 TSC2 ND4L CEP290 DSP ZNF423 FMO3 NDUFAF4 DPF2 FOXP3 DACT1 CRYAB TWNK SF3B1 GNE SMOC1 NR3C1 SULT2B1 TERT KLLN BAG3 ELANE YARS2 TRNF GAS2L2 XPA LMX1B PRKACG KCNJ5 IDH3A AKAP10 MC2R RASA2 DHCR7 RBP4 HJV B9D2 RASGRP1 RHO LDLRAP1 NRXN1 SH2B3 PRPF3 TMEM237 KIF7 KIAA0753 LMNA KLF13 MUC5B RLBP1 TSR2 TSPYL1 NNT HNF4A TP53 TKFC LMNA NDUFA2 VIPAS39 FOXC1 ANKRD11 KCNJ8 KDM1A IFIH1 LRP5 MOG EIF2AK4 HBB SDHA XYLT1 AIP PACS1 SRSF2 PTPN11 CPN1 PLOD1 SGCD DNAH9 CACNA2D1 TMEM43 F9 FSHR WHCR COL1A1 ELOVL4 NLRP3 TGDS HMBS HCCS TREX1 SOX18 CEP19 DNASE1 DES ACADVL CYLD ROM1 NOTCH2 SCN5A WT1 DGUOK IFT88 FERMT1 VAC14 KIF1B PIK3R1 USF3 GYG1 DNAJC21 LIPA CCNQ COL1A2 CDAN1 SDHA FXN PEX3 POMT2 CD109 EIF2AK3 PSAT1 ENG TTN SKI IDUA PRPF31 KRIT1 CLEC7A NEXN KPTN MRE11 MAP1B DKC1 RPL26 GATA1 PDE6A ARID2 TET2 TET2 HBA2 FUCA1 GABRA3 ALOX12B CCDC39 PLIN1 FGFR3 ATRX HAAO FMR1 MYH7 BACH2 SGSH ARID1B PTEN STK11 SCN1B KCNK3 SOX9 GPC3 EDA2R OSTM1 CTLA4 TNNI3 PDGFRA GATA6 SFTPC KCNQ1 BOLA3 CBL APOE TTC37 CHD7 HSPG2 COX7B MTRR STN1 RNASEH2A MCCC2 NFIX PROC CYP11B2 MSH2 IL6 POLG2 CCND1 NCAPG2 ATP7A STX3 GAS8 DGCR8 LMNA TRIM32 GIGYF2 TCF4 AKT1 TRNK TMC6 RASA1 HPS3 HRAS FGA SETBP1 IRF2BP2 HIBCH SLC35A2 TFAP2A SEMA3E PIGQ CHST14 PLEC ACTN2 CHRND INPP5E PKLR GINS1 CRYAB PEX10 NEK1 ESCO2 ECE1 AGBL5 WRN DVL1 KLHL3 BRAF NKX2-5 POU6F2 DAXX C4A DES ALDH18A1 RPS28 FLCN COL4A2 PSMB8 TCAP LAMA4 FANCA DMD KLHL7 DGCR6 WFS1 NCF4 RAG1 TPP2 ADD1 RAB23 F5 SGCG XRCC2 TMEM67 NKX2-5 CDON B2M CRTAP TP53 PIK3R2 DCAF17 FKRP GATA6 SUFU ERCC4 ALX4 OFD1 ATAD3A DCLRE1C SCNN1B ACAT1 MBTPS2 CACNA2D1 TPM1 ND5 LARP7 MUC5B NDUFS8 LIAS SP110 FAS MYH3 DPM3 PIGY BAP1 FANCM ETHE1 DHDDS KCNJ5 SNX10 ERCC6 NKX2-5 MEN1 GPC4 HNF1A XRCC4 TET2 FHL1 MUC1 RYR2 DGUOK DNMT3B ARMC9 SDHB POMT1 MAP2K2 NCF1 RBM20 CLIP2 ALX3 POR IFNG DCDC2 STAT4 HLA-DRB1 PRKACA F2 KCNN4 PLEKHM1 MAFB NDUFS2 PKLR PCGF2 NEU1 GTPBP3 NOTCH1 HIRA DKC1 KCNQ1 STEAP3 AKT1 RNF125 TGFBR2 FGA CPLX1 WFS1 AIP TGFBR1 MYL2 GNAO1 DYNC2I2 SOS1 CYP24A1 MYH7 RERE DNAJB13 TBC1D24 HLA-B SDHD WNT3 BRCA2 SERPIND1 FLNC PROKR2 TRNL1 DDB2 GREM1 ANAPC1 GPD1L RIN2 FBN1 SMAD6 ND3 TGFBR2 RYR2 ND6 MED12 COL4A1 NOTCH3 CCNO AGXT PIBF1 SLC26A3 CR2 IL2RA SLC7A7 NDUFA4 CAVIN1 PROC KCNQ1 TPM3 IGF1R ANKRD26 PEPD GJA1 BAG3 LYST KDM5B SLC25A11 ALG8 ATP6V0A2 ERBB3 RPL27 ACTN4 ADA2 PMM2 RET DYRK1B COL2A1 TRNL1 POLR3A EPB42 BMPR2 GNB5 ND1 CRELD1 PIK3CA RNU4ATAC MSX1 GPC6 MGP PSAP IFT172 NDUFB8 VHL ANKRD1 KCNQ1 NGLY1 PPP1CB KRAS MITF SCN5A SALL4 TRAPPC11 ALB ERCC5 ATRX EPB41 PHOX2B CTNNA3 CFAP221 RNU4ATAC B3GALT6 SDHD LAMA3 ZIC3 GGCX B3GLCT RAI1 SALL1 CDKN1B F2 STK36 BBS5 IDH3B CAV3 NEUROG3 PUF60 TRPM4 DHX37 SDHC MALT1 SDHD ATPAF2 TXNL4A KRT2 HS6ST1 PSAP DDRGK1 KCNE2 NME8 TRNE ND1 UBE3B COQ2 BMP2 NAXD LMNA COX10 FKRP MKKS CYP17A1 TRDN THBD BTNL2 EYA4 TGM5 BCL10 FBN1 TNFRSF13C PDGFB ALG9 FANCC LIG4 ACTA2 FLNA TCTN3 GNAS IKBKG PRKG1 SERPINA6 AGTR1 CFB GDNF POMP KAT6B NHLRC2 TRMU KCNJ2 RPGR HADHA FANCB PKD1 FANCD2 SCN9A TCIRG1 ZIC3 SCN9A SLC39A4 POLG ADA LIPN KCNE1 CERKL GCH1 BAZ1B CYP7B1 PCSK9 SFTPB PTH1R CTLA4 BCOR LRP5 PPCS DYNC2LI1 TGM1 ASS1 PPCS GYPC MPL COL1A1 COL4A5 TP63 CFC1 TSHR NONO COA8 ACTG1 MYH7 CLPB SCN5A THSD1 PIGA ARID1B DNAAF2 NPHP4 JAG1 BAP1 CRLF1 NOS3 MMUT KIT FAH SRD5A3 CDK8 STAT1 IFNG SDCCAG8 MED25 PAX3 HCN4 CRYAB KIF15 RNF113A GNPTAB ACTG1 IRX5 ZMYND10 PIGL SEC23A PIK3R2 AIRE MYH7 AIRE SF3B4 PIGV FMR1 TXNL4A COL1A2 PIK3CA AKT1 AAAS NFIX GBA PACS2 DIS3L2 KRAS DNAJC19 KRAS JUP APP ALG1 NDUFA1 ACTA2 DLL3 NDUFA11 CYP17A1 NOTCH1 TNFRSF13B CASR FLII LDB3 CHRNA1 TRPM4 C12ORF57 AKAP9 MC1R ATP6 CSRP3 NSMF IL10RA BBS1 CUL7 TOPORS NDUFS2 OPA1 TSC1 SLC40A1 ATP6V1A FBN1 HMBS FHL1 CTCF PRKCH C8ORF37 SPTA1 DLD F8 CXCR4 ARL3 GDF6 LRAT PEX7 GATA6 ADK SLC20A2 ABCC6 FGF23 AGPAT2 ATP5F1E CTLA4 ATP6V1E1 FANCA SUMF1 DSP OTX2 OFD1 CD27 CASP8 RPS19 POMGNT1 KCNJ5 TNFSF12 SPINK5 MPL STIM1 PNPLA2 SLC19A2 CFHR3 RPS19 POMT1 FCGR2A NEXN FEZF1 SUFU TP63 BAG3 NOS3 LIPA NKX2-1 DNAJC13 TMEM231 TTR MPLKIP VHL LRP1 BIRC3 ESR1 FBN2 FANCL EPB42 GNAS LAMP2 DDX59 ND2 RAF1 MAP3K7 ITGA2B PEX7 IL12A-AS1 MLX FGFR2 PCCB TJP2 MED13L PORCN CD81 MRPS14 THPO MYRF MRPL44 HAMP KRT5 CTNNB1 MMP14 KLF1 TRNT1 DBH TRPM4 SERPING1 PCNA TERT BRAF PET100 HLA-DQB1 TNNT2 PRKCSH AEBP1 EVC PEX6 ACVRL1 TELO2 COL2A1 FADD GCLC FIBP KCNQ1 TAF2 RGR FADD SNIP1 SCO2 NDUFS2 NDUFB11 SLC25A22 KCNE3 MRAP ADGRE2 CACNA1S VPS33A HSPA9 NF1 SNCA FLI1 CD46 OTULIN CLDN1 GAS1 FASLG COX3 FANCB LMNA C2CD3 MTHFR ROR2 PQBP1 GATA1 SDHA SMAD4 SNRPB MEGF8 CYP7A1 KIAA0319L KCNE2 AP3D1 PEX1 COQ4 ATM ARVCF BPGM CRX RAG2 CKAP2L INVS NFKB2 KIF5A JAK2 KIF7 TGIF1 FOXRED1 SOX3 FKTN IQSEC2 DMD COL4A1 LAMB3 TNFSF11 SDHC RBPJ HBG1 KCNQ1 NDUFAF4 CISD2 IL2RG PLAU F5 TBX2 RNASEH2B GMPPB SCN11A GLRX5 MAF PLN VPS45 NPM1 ND5 USB1 PEX16 NOS3 ELN SLC2A1 STAG1 HADHA MYH11 RBM10 STAR PORCN MYH7 MYH9 NKX2-5 RET GSN CDKN2A PSMD12 MYPN NOTCH3 GJA1 NCF2 SLC39A13 MEIS2 FOXC1 IDH1 PRPF8 FOXP1 SOX10 RNASEH1 ERCC4 NDUFS8 ND5 STIM1 CYP11B1 MEF2A ACTA2 ATP7A TERC ELN GPX4 PMPCA EMD VAMP7 GLB1 JMJD1C SYNE1 VANGL1 RPL5 CEP120 IVD NLRP3 PKD2 FLNA MED13L AUTS2 TRIP13 GNAI2 CACNA1S NRL FLNA CARD11 NAA10 TMEM126B POLR1C COL1A2 PROC STK4 SDHB SCO2 BUB1B SCN2B PTPN11 DLX5 SOX4 GNPTG JAK2 MTMR14 NR5A1 YY1AP1 NDUFAF2 RMRP ARID1A CSNK2A1 USH2A TCTN3 SETD5 CPT2 SF3B1 TK2 TRNW SCNN1G SOX2 TBX1 SPRY2 NOTCH1 CPT1A JAK2 NDUFA2 TRAF3IP1 CFAP298 P2RY11 CEP290 SERPINC1 TMEM67 KCNJ18 FZD4 GBA NGLY1 SEC24C COL2A1 MECP2 MAX ATP6 TMEM107 FGFR2 FGFR2 FTO LMBR1 HADHB DSP COL7A1 RB1 SLC25A4 CLRN1 MEIS2 SNRNP200 RIPPLY2 CYBA SHANK3 GDF1 NDUFAF5 TMEM237 NOTCH2 NAGA SMARCC2 SDHAF2 STAG2 PEX19 CD81 PDGFRA SIM1 TRNE FHL1 PPARG PARS2 SGCA ZFPM2 SMG9 CLCF1 TMEM127 ETV6 TTC7A NIPBL IDH2 GTF2H5 GMPPB RPGR SCNN1B PHYH CAV1 ENPP1 COX1 PEX26 SCARB2 HFE KCNA5 PEX5 ACVRL1 ARL2BP NFE2L2 INTS1 CYP11B1 SYNE2 AKT1 IL17RD TTN FGFR2 ABCC9 TRIP13 RAG1 ITGA2B CFAP300 RIPK4 PRPF3 PAX6 SMC3 ALDH18A1 IDH2 RHBDF2 TTC37 CD28 FARSB LRP5 NPC2 RERE SELENOI BMPR2 NRXN1 SCN5A ZMYND10 TMEM67 RBBP8 TRIP11 LZTR1 COL3A1 FREM2 SALL1 ATP6 CYP27A1 NUP107 PLIN1 NKX2-5 IKZF1 PEX13 POLG AKAP9 EXT2 RARA TPM2 NEK10 ARMC4 AGT LIG4 UBE2A SSR4 EGFR APOC2 SLC2A10 RPS6KA3 MAP2K1 PDGFB PTEN ND1 CEP120 GJB6 RDH5 ABHD5 NDP AHI1 ISCU SERPING1 PNP COL3A1 ITGA7 NDUFB11 NPHP3 TRNK HLA-DPA1 NEK8 RARB PLN PRKAR1A SLC25A13 TLL1 HLA-A CNBP DVL3 NLRP3 MAF ADNP LBR TANGO2 PKHD1 ATP6V1A FANCD2 SNCA BICC1 SBDS FAM149B1 ACADS BMPR1A COX2 GTF2I MID1 MVK KIF23 MYBPC3 DNASE1L3 KCNE5 THOC2 FGFR3 FLNA IFNGR1 ISG15 PEX6 TP63 D2HGDH LTBP2 DDX58 EZH2 IDH3B F8 SLC29A3 TBX6 NF1 SOX10 STAT3 SCYL1 TMEM260 ATAD3A HLA-B GLI2 ITPR1 PTPN22 SCNN1A EBP COL7A1 EDN3 LDB3 BIN1 WT1 LIPC ABCD4 HPS1 PROK2 SIM1 WASHC5 LPL SLC12A3 PHF21A CYP27A1 ARNT2 HNRNPU STING1 FIG4 FANCC GUCY1A1 PTPN14 SIK3 IRF6 POLD1 SDHB TMEM216 ACTA1 PEX14 PRKAG2 NR3C1 SUZ12 DNAAF3 HBA1 IGF2 GJA5 MYPN SETX ND2 POLH CYBB CALM2 KCTD1 FSCN2 HADHA TCIRG1 SEMA3A GP9 AP1B1 LYST LMNA TMEM231 TNXB CDH23 IL7R BTK SARS2 ELN STAC3 FLNA SMAD4 MAP3K20 PGAP3 FOXE3 NFU1 MKS1 MYH11 MCFD2 ACTB FECH FLI1 PUF60 KRAS

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0001626: Abnormality of the cardiovascular system
Genes 4136
TWIST1 KRT14 ELMO2 SDCCAG8 KCNJ1 TCIRG1 MICOS13 MTAP RAG1 INSR ELP1 KCNAB2 TSFM HEPHL1 RNASEH2C CD19 EPCAM DNAH1 NF1 EYA4 SIX3 ASAH1 LORICRIN CTSB NDUFS7 GPR35 TMEM138 MFAP5 CYP11B2 GNA11 SHOC2 RDH12 HCCS SF3B4 GLA CC2D2A CCR1 PIEZO1 ATP8 TRNL1 CCR6 TTC7A PTCH1 DSP EPHB4 ANOS1 CALM1 B9D1 F5 ERCC3 MPIG6B TTPA FHL2 GBA CFI ALAS2 ATP6AP2 ROR2 COQ2 CLCNKB BSCL2 HPS4 SLC7A14 PIEZO2 IFT43 GBA BCL2 PHYH SLX4 INSR OCLN CHRNG ACADVL SARDH PAX8 TREX1 SFTPC NSMCE3 SLC19A2 SFTPB NFIX RPGRIP1 KRT5 IGFBP7 AQP2 AKT3 DYNC2I1 TRIP11 RPE65 KDM6B TNNT2 BRF1 NBAS RAI1 FOXF1 PHGDH FLRT3 F11 EVC2 WT1 COL5A2 ZFPM2 SDHA EBP CHCHD2 TNNI3 ATF6 UFD1 LETM1 NDUFAF3 DDC TDGF1 HTRA1 MEGF8 TMEM126B HNRNPA2B1 ACTC1 SDHD SEC61A1 ICOS ZFPM2 CD3D IRF5 GPC1 FOXJ1 FANCE CHRNG JAK2 PCCA GANAB PPP2R5D DNMT3A DCC POU3F4 ANKRD11 EXTL3 DEAF1 TAF1A MMP2 VWF PYGM HESX1 HLA-DRB1 ACTG2 MIB1 TWIST1 SMAD4 WNK4 PEX12 ERCC3 LBR ALPK3 SMAD4 MAFB C8ORF37 F2 ATP6V0A2 SOS2 LEP BRCA1 CEP41 GP1BA GJC2 FBN1 CERKL DOLK KCNE1 MSH6 CFHR1 CREBBP OTC OTUD6B POLG DNAI2 PLG SH2B3 PKD1 ACADM BCR MITF IGLL1 IRAK1 ND6 TERT NSD2 PPOX FBP1 LEPR PEX2 HMGCL ATXN7 RPS17 MYL4 FOXP3 SLC25A3 VPS13B PRPF4 NODAL FLT4 KCNA1 PEX13 SMARCE1 TTC8 NKX2-1 MTFMT MEOX1 NAA10 TGFBR2 NDUFB3 XYLT2 PBX1 CDKN1C MTTP CD244 PIGT PKD1L1 NDUFAF3 H19 LEMD3 ABL1 CFTR PYGL CYP1B1 CHRM3 LMNA CDC45 CCDC114 HGSNAT ADA HLA-DRB1 RAF1 DCHS1 TAPT1 NLRP3 DLL1 ND6 EVC2 RP1 RECQL4 POU1F1 CST3 CTSH SDHC ASAH1 SDHD NLRP12 ABCC9 SOX4 KCNJ2 XPC PRDM16 ACSL4 MNX1 MYO18B RTTN MCIDAS ABCC8 STXBP1 DTNA GDAP1 NPHP3 PIGM A2ML1 NUP188 POLA1 GUCA1B GUSB TRPC6 OTC ND3 COG7 PDCD10 C4A AVPR2 CD79B APOE AMER1 MYOT FZD2 PLOD1 HLCS MED12 PROP1 CANT1 MYF6 TNFRSF11A ARHGAP31 PRKCSH KCNH2 PDE3A ORAI1 KCNQ1 SMCHD1 PDE6B TMEM237 SDHC KCNQ1 TSC2 CFTR PEX7 C1QBP WWOX CFAP298 SCN2A NAGA CYB561 PRDM16 MMUT WNK1 ABCG8 ALG12 GLI3 HGD NDUFS1 CALM1 BLM TBX5 GALNS COL4A3 SOX10 ZBTB16 CYTB ANTXR2 NAGLU PPA2 TMTC3 SDHA DYNC2I1 FLT1 FLT4 HCRT CCDC39 ARMC4 HLA-B ABCA3 BCOR POR COL1A1 APP FAS TPI1 MBTPS2 NEU1 APOA5 MMP21 PRG4 JAG1 LRP2 MYH7 FLNA F13A1 PTPN22 TWNK KRT14 KYNU COG2 NAA10 MYL3 CENPF RYR1 FLNC VPS35 SOX2 TRAF7 GATA4 SDHA ATP7A ZDHHC9 TREX1 KCTD1 TRIM28 POLH CYP7B1 PIK3CA BBS12 SLC12A3 MVK MYOT GFI1 CYP11B2 TAZ TACO1 TET3 IGH ATN1 COL4A4 KIAA0586 WT1 RRM2B PSMB9 C3 MAPT TRNS1 NFKB1 HFE GBA BMPR1A ERCC3 TET2 HLA-DRB1 MFAP5 EPG5 KYNU PIK3R2 HADHB APC XIAP CLCNKB BRAT1 CDC73 MS4A1 BRAF FAM111A NAGA TET2 FMR1 APP ND2 MIF SCN5A STAT4 GFI1B BBS7 CDK13 UQCRFS1 GJB2 TPM2 HRAS UROS SNAP29 ADAMTSL4 RAD51C GNPTAB SDHB HBA2 CDC42 TRNL1 IDUA TBX1 POLE CD96 CALR LMNA GMPPB DPH1 OFD1 OTUD6B ITGA2B CAV3 LZTR1 TRAIP GGCX IL2RG DCTN1 CYLD ENG DSG4 CACNA1C POGZ PHKG2 PDE11A TFAP2B ND4 FAM161A MGAT2 WDR19 PARN IDH2 ASXL2 SMAD4 NR3C2 USP45 PRKAR1A KDSR GPI FBN1 VCP HELLPAR FASLG NR0B1 ABCC9 DMRT3 FOXRED1 HOXA11 KRT1 CDK10 POLG MERTK RPGR HBB CFHR1 SCNN1G ETHE1 CBS HLA-DRB1 TRNV PSAP TGFBR1 SLC25A26 NDUFB11 AHI1 CD46 RRAS IARS2 KIF7 MAT2A IFT172 CALM2 ATP2C1 GALE CCN2 WNT10A TBX3 RPS6KA3 B4GALT7 POMT2 OSGEP ROBO4 RSPH1 TMEM231 LIMK1 PDE6H LBR MINPP1 MRAS PRRX1 PSEN1 LMNA JAK2 HLA-DRB1 AFF4 PDE6A NOTCH3 DNM2 CNGA3 ELN NDUFS8 CTSK COL1A2 LMNA GBE1 RRM2B ATP6 POLR1A GNAQ SYNE2 ADA2 CACNA1C EPB41 HSD3B2 NRAS DNAH9 FAM13A SALL4 HADH DNM2 CHRNA7 NSDHL XPC DMD NDUFV2 GATA1 SHOC2 AGK TNFSF11 ROR2 HMGA2 LRP6 TNFRSF13B TRNQ PROS1 CDKN2A POLR1D COX3 XYLT2 MYH11 COQ2 AGK GATA4 TNNT2 MTOR SRCAP MYMK B2M DOCK6 LRP2 MYSM1 MGMT CTCF AGL TOP3A F2 NDUFB10 FRAS1 SCNN1A IRF5 ABCC9 SDHD NRAS SOX2 TECRL SKI NBEAL2 GP1BB CORIN ZNF365 C1R PRKAR1A CTSA H19-ICR B9D1 LAMA2 EXT1 INPPL1 AGT XPR1 UNG SLC25A4 NKX2-5 DST FIBP PIK3CA DNAAF6 LMNA SCN10A FOS CCDC141 CPLANE1 CCDC141 JPH2 HFE KAT6A VEGFC JAK2 STAMBP FGFR2 LEMD3 TMEM216 PPA2 CLN3 LMX1B TRNS1 ANK1 LMNA SDHC PEX11B MED12 PCCB TMEM237 ALG10B IL12A PRF1 KCNJ2 FLNB FCGR2B RHO HAND2 KCNQ2 KIZ CLCN7 CC2D2A SMAD3 IDUA ABCC8 ADA2 DSP TMEM43 BBS9 NABP1 NLRP1 TCIRG1 SKIV2L HCN4 FERMT3 ENPP1 MTM1 LZTFL1 WNT10A MGME1 TNNC1 DNAJB11 CHKB BRCA2 NELFA NT5E COX1 TBL1XR1 GJB4 CCND1 NR2F2 TRRAP ZFPM2 RPGRIP1L PROM1 RYR1 PYCR1 RYR1 DNAI1 DNAH1 DPM1 CYBB ND6 SNAI2 TARS1 ALMS1 ELN HJV PNPLA6 DMD KCNE1 F10 RAG2 TERT STX16 COL5A1 FGB NUP107 KIT GATA6 PLP1 ATP6V1E1 CA4 LHX4 DPP6 STRA6 PIEZO1 FBN1 PSMB4 PCARE LRRC6 ABCC6 SUFU COX2 DNAAF5 WNT4 RET STOX1 SCNN1A IRF5 LTBP2 TFAP2B USP9X INTU HDAC4 SPECC1L CTNS MGME1 TTC8 FAS CYP11B1 SLC2A1 CPLANE1 CCDC151 SPAG1 GDF1 PEX2 TERT NPHP1 PRKAG2 DPP9 AARS2 AMER1 LIFR KCNE2 NFKBIL1 SDHB SCO1 NDUFAF6 ARID1A RPS24 PGM1 GATA5 KAT6B NOP10 FGFR1 IFT80 SEC63 COL1A1 RBM8A MYMK MAP3K1 SLURP1 TAZ TBX1 SRCAP CPT2 CTNNB1 TCAP HBB KRAS COX7B SAMD9 GATA6 COG4 PML SLC29A3 SERPING1 GP1BA ARX DDB2 COG8 TOPORS WDR11 SCNN1B ADAM17 KIT GATA6 CENPE DNAAF5 NPPA ND4 RPL26 CSPP1 SLC25A20 GNAQ KLHL41 SCARF2 ECE1 SEMA3E ANTXR1 AKR1D1 CHD7 CC2D2A VCL ADAMTS2 GPR101 FLNA FERMT1 ATOH7 MAN2B1 LMX1B RAB3GAP2 ATRX CEP290 MYORG BCL6 TP63 MCM4 FANCG TRAC FUZ HDAC8 ZNF469 ASXL1 STAT3 IL7R KATNIP ITGA2B FBN1 ANK1 FCGR2C COQ7 COQ2 NLRP3 HTRA1 TAZ ALDOB NDUFAF5 LETM1 DHODH AVPR2 RPL27 FANCI APC2 PIGA FBLN5 ACP5 SLC39A13 NRAS MYH7 PNPLA2 NUP155 RPS15A PTGIS CRPPA CDH23 EBP GTPBP3 KRIT1 FOXE3 EWSR1 SNX10 APOB RPGRIP1L ASXL1 SF3B4 PKD2 FBP1 SMO ANK2 NOTCH1 ABCC6 THOC6 PRCD NDP TRAF3IP2 FAN1 BMPR1A VPS33A NOTCH2 ERCC5 EFTUD2 CHST3 DYSF ALOXE3 ENG GANAB TTR INPP5E CD247 PRKAR1A EMD LIPT1 CACNA1S ANKS6 WAS CASP10 PIGT SAMD9 KCNN3 CA2 ATP7B PDE4D FBN2 POGZ ANTXR1 SLC26A2 GJA5 FGG RNF168 RP9 PTF1A KCNH2 BMPR1A POU2AF1 EHMT1 COX4I2 MPL DNMT3A ARMC5 MYPN DNAH5 RPL10 KRT1 EPHB2 INVS PQBP1 ACTC1 NKX2-5 FRG1 TECRL HEXB LMNA KLF1 RARB CEP290 GRIP1 GLI2 FOXA2 GYG1 TMEM127 CD79B KAT6B TBXA2R KDSR CALM1 HCN4 ADA2 PIK3CA IDH1 KRAS CACNA1H IRF8 ND5 KRAS COL6A1 NDUFAF1 NDUFS3 COL11A1 FBXL4 SMARCE1 COL5A1 PRPH2 TRIO MAP2K2 PEPD RPL35 DNAAF2 SLC25A3 ARF1 SEMA4A AP1S1 TGDS CD70 LMNB1 MAX TULP1 SNRNP200 FHL1 TNFSF12 CDSN ACTA1 GMPPA USP9X BBIP1 HLA-DQB1 NHP2 ANGPTL6 FBLN5 CWC27 PEX16 NDE1 SLC22A4 CHD7 HPGD GATA6 TKT PTEN TET2 BTD EVC BCHE TALDO1 FLNB EED ALDOA JAM2 CFAP53 USP8 PGM3 FGFR1 AP3B1 FLNA JAK2 SOX18 STIM1 PDGFRB KMT2D POLR1A GLI3 GLB1 GDF2 NEB IFT172 TSC2 CDIN1 TNNT2 NEK9 F7 KRAS BLNK GBA WDPCP CSRP3 REEP6 LMNA KCNN4 TNNI3 TP63 KIAA1549 RRAS2 MEFV ACTA2 KCNH2 TERT SACS RPL5 BRIP1 RUNX1 DDX11 KRAS TPI1 MED25 SALL4 ATM EYS KCNH1 GPR101 IGH DOLK BANF1 PEX1 GATA4 REN DHPS ND4 GPC3 MLH3 FAH RNF213 PRKG1 EXT1 RAF1 TRDN KCNQ1 CFH COL3A1 COLQ PAFAH1B1 GJA1 COL11A2 RUNX1 BCOR SDHB ALB CFI SLC7A7 TBX1 RNF113A RAI1 SLC37A4 TF PTCH1 RPGRIP1 CEP120 DLD RLBP1 PDSS2 CKAP2L EDNRA KCNH1 GALNT3 PCCA PALB2 MAP3K7 NFIX WT1 TAB2 SMARCB1 COX8A PAX3 THPO NRAS STX11 AGA RAD21 TBX19 F12 KCND3 MNX1 CEP290 ERCC2 GREB1L CD40 BEST1 CYTB TPM2 TRPM4 SLC25A20 MYOC MYH9 CLCN7 RET MST1 PEX12 DSE NDUFS6 ARSB TCTN1 NDUFA11 GJB6 SCNN1A KISS1R TERF2IP MPLKIP GPD1L OFD1 PDGFRB HYMAI ALKBH8 DNAAF4 LDB3 FGFR2 LRP5 GATA4 UNC13D MEOX1 ARL13B CYP3A5 ERCC2 WNT5A AGPAT2 TINF2 RHAG HSD3B7 GNE ATP11A NPHP1 ABCA1 PMM2 CEP104 GNAS ARL6 GTF2IRD1 TPM1 SDHD FANCB CDHR1 NF2 RAD21 NPC1 GPIHBP1 COL18A1 CEP57 CNGA1 TBX1 FGA LDLR POLG SMO NF2 SELENOI CPT1A CTLA4 ZMPSTE24 DPF2 C12ORF57 DIS3L2 SUMF1 OFD1 CD3E POMGNT1 NEK2 NEBL CAV1 ACTC1 MAK GCK COG6 BBS2 COMT XYLT1 SLC4A1 PEX5 DPM3 GP1BA RMRP RSPH9 GLIS3 SCN5A ERF DCDC2 RAB27A TP63 ERAP1 SOX5 TAF2 AIPL1 PEX19 TGFBR2 TNFRSF4 MYOC IL6 SRY PTDSS1 PDE6C PMS1 RAC1 TMEM94 ELN VWF MMP1 SEC23B CIITA RPL35A TEK CHRM3 LCAT ALX4 PRKAR1A MDH2 GSN G6PD CNGB3 GATA5 CYTB POLG FGG SCN4B MKS1 TTC8 IL2RB LMNB1 CAT SIX6 PARN IQCB1 TRPV3 MEFV GATA4 SH3PXD2B SDHB PACS1 NDUFA10 BCS1L PLAGL1 PRKCD SLC4A1 TALDO1 TUB ERCC6 ABCA1 BTK MYPN ELOVL4 NR2F2 HK1 SLC12A1 STRA6 RPL35A HBB RPS20 KMT2A AGA RPS26 ACTG2 KRT5 NCF1 MYC RAB23 ACTN2 MKS1 COL1A2 ARID2 NFKB2 ND2 ALX1 LRRC56 MTHFR EIF4G1 F13B SOS1 ACTC1 SGO1 CTC1 IFT122 FGFR2 CDKN2B SMAD3 HDAC8 MTO1 THOC6 SCNN1B HAVCR2 HBA2 UVSSA DNAAF6 CCDC8 FGA DHCR7 GLUL TREX1 GPC4 IL17RC TSC1 CITED2 CCM2 TCTN3 XRCC2 SERPINC1 RECQL4 PEX16 BEST1 SETBP1 MYBPC3 CASR KRAS SMAD6 TFAP2A NDUFA13 SLCO2A1 PTEN TDP2 RPS26 GFI1B KRT14 COX7B GYS1 SLC18A2 GNA14 PRF1 DSP COX3 PIK3CA RPS29 ND1 SCNN1A KCNJ18 CD40LG ARFGEF2 GATAD1 LOXL1 GP9 RSPRY1 F5 LRIG2 TRIM37 PSAP HLA-DRB1 FOXE1 F8 JUP FOXE3 TNNC1 NKAP SEMA5A RANGRF CASQ2 GBA GJB2 SMAD4 TNNI3 MAP3K7 AQP5 LMNA ABCA1 RB1 KCNJ11 ANK1 CRELD1 TGFBR2 MYH8 H19 ALOXE3 GPD1 EED PEX6 SOX18 FXN SMPD1 CALM3 MYH7 COL6A2 NF1 PTPRC SDHAF1 IKBKG CYP11A1 BIN1 MC4R ABCB4 DVL3 PLCG2 DMPK HEXA POLG2 ABCD3 TRNS2 PAFAH1B1 KRT8 NDUFS4 DNAH11 DCLRE1C POT1 PIGO SMOC1 APRT CDKN1A SDHD ARX ITGB3 FGG CAVIN1 FLNA CUL3 TMEM126A LDB3 SFTPA2 TTN PLCB4 HPGD SLC25A4 RIT1 PCNT DNAH5 CEP41 ZNF423 NONO RGR PQBP1 MAP2K1 YWHAE CCDC151 PTEN SCN1B MEN1 HYLS1 SCN3B KCNE5 TPM3 SLC35A1 TACR3 IGBP1 CHST3 IL12B SPEG SLC30A10 XPNPEP2 RYR2 ATM NDUFA6 IFT81 SURF1 SEC23B KLHL7 MEFV NBEAL2 SLC52A2 GATA4 DPH1 RPS17 EPHB4 KAT6B CEP164 PUF60 BTNL2 SMARCB1 SLC25A24 TNNI3K CTNND2 BRAF PGM3 DUSP6 ERCC2 PLD1 PDHA1 SMAD9 TBC1D24 CHD7 BBS1 ALG9 GJA1 CD28 MAP3K7 CCDC40 PNKP POR JAK2 GLI3 EXT2 CCN2 GPX4 EOGT ARL6IP6 AMMECR1 HOXA1 HIC1 FOXF1 NPHP1 GP1BB AHCY VCL TRNK EPHB4 GABRD PIEZO1 COLGALT1 SMN1 RSPH3 PRPH2 APP COG4 SMARCA4 GJA1 ITK KIF20A APOA1 HYDIN RET NOTCH3 RHOH JUP CASQ2 ANK2 CCR6 IFIH1 PLEC SNRPB HYLS1 C8ORF37 PRKCD SETD2 TGFB1 SCN1B GNAS GUCY1A1 IDUA CRB1 IL7 DNAH11 CCDC47 SPAG1 GJA5 PDX1 CPT2 TNFSF4 FBN1 FGF20 SH2B3 IL36RN STAT5B WRN COG7 APOA1 ARID1B SPTB FOXH1 NXN PRKAR1A ERBB3 GMPPB ECHS1 PNP ATP6V1B2 ZAP70 WRAP53 SMC1A STAT3 DNAAF1 FGF8 BMP2 LIMS2 F10 CP ITGB3 DBH LRBA TRNK GNB5 SOX11 F7 KLRC4 ATP5F1A NDUFAF2 PIEZO2 CRB2 AGXT NDUFB11 HSD17B10 WDR26 TNNI3 PRNP PALLD HLA-B PLCG2 NOD2 CTLA4 COL1A1 B3GALT6 MGP FGD1 HSD3B7 GBE1 CALM3 DNAAF4 NF1 MAN2B1 GPC4 TIMMDC1 NDUFAF8 RAD21 SNTA1 TMEM70 STRADA PRDM6 KDR DES MCTP2 PIGN AKAP9 EMG1 COG1 TFRC INPP5E HBA1 RPL11 KRAS PTPN11 SKI RBP3 HABP2 LAMP2 VPS33B ZNF513 FOXRED1 CCM2 SCN5A MKKS LDLRAP1 GALC SEMA3A TRNQ B3GLCT EXT2 RBM20 CCDC103 CLCN7 GNPTAB GBA EDA UBE2T AHI1 BNC2 SLC25A4 F13A1 COQ9 ATP8B1 APOE SMC1A PEX1 EDN1 PPARG CDKN2C ENPP1 GATA5 LRP5 SLC19A3 DLEC1 CCND2 EFEMP2 SGCB PEX5 CAV1 RBM10 TBX1 SPIB RFC2 NLRC4 SDHAF1 MCCC1 IL2RG SRP54 RAF1 GGCX TSC1 CCNQ LTBP3 GATAD1 SCN5A DVL1 NEB PTPN11 KRT9 CSTA FGFR1 CIB1 SCNN1G BBS2 DSE LRRC56 COA5 XK CASR DNAL1 MYCN SCN5A GATA4 TMEM70 ARPC1B LRP5 RPS7 HBB JUP TRNS2 TNFRSF13C SPTB UCP2 DVL3 NEK9 JAK3 MYPN IDS NDP DSC2 ND5 NFIA CITED2 MSX2 RYR1 SERPINF2 VWF CACNA1D EPG5 EHMT1 TCIRG1 CLRN1 CR2 POMT2 ELP1 B3GAT3 PADI4 TAB2 ACTA1 MKKS SMPD1 TSC2 MVK PLEKHM1 RNU4ATAC SELENON LTBP4 DDRGK1 BRAF AIP POLR3A ABCC9 FZD4 NR2E3 PTCH2 CCBE1 DCLRE1C PPP1R15B GBA MYLK TET2 TRPS1 ALDH3A2 ASCC1 PIGS TNXB ADCY5 CPOX CSRP3 SGCD GNAQ BSCL2 PPARG NEUROD2 PDSS1 FN1 FLT4 ABL1 NDUFA9 SPRY4 MAP2K1 LAMB2 CNGA1 TRMT10C DNAAF3 FLNC TNFRSF1B POMT1 GPC3 PGAP2 ND6 KCNJ8 TNFRSF1B TTC8 FANCE JAK2 GATA1 FGFR1 FKTN CHST14 PDGFB RFWD3 ELAC2 CPS1 COL4A1 RPSA TGFBR3 TGFB2 CACNB2 TTC25 SURF1 WIPI2 CDON PROP1 CHD4 GJA5 ACE HADH IGSF3 COQ2 GNS NPHP1 HPS5 NT5E APOB SDHD SMARCA2 GDF3 ABCB11 PSEN2 SPEG FH ADNP EXOC6B LONP1 SAMHD1 YY1AP1 PEX26 NOS1AP CALM1 SEC23B BRCA2 SLC26A2 JAK3 FIG4 SGCD GTF2E2 CASK CIZ1 XPNPEP3 HBA1 ZNF687 CARD9 FRA16E TF PSEN1 PKP2 C1S TRNV CYP11A1 KRAS MLXIPL RNASEH1 PRRX1 GNAI3 UBAC2 DNAI2 APOE HES7 ABCC9 MYH7 MYH6 TMC8 PCNA MED13L OBSL1 NAA10 NDP RORC CHN1 NSMCE2 VHL ATP6AP1 UBE3A CSF2RA SMARCA4 AK2 FIP1L1 FGB SAG PEX2 TGFBR1 LRRC8A SHPK DSG2 PLOD3 TLR4 HPS6 RMND1 ADA CFAP300 CYP21A2 NKX2-6 COA6 SLC4A1 COPA RHAG RPS15A GATA1 LPL SC5D SDHA RBCK1 RS1 GDF2 PAM16 DHX38 FLNA PTEN APP KBTBD13 IL10 SHH COG5 NPM1 SLC37A4 ND1 SAMHD1 RPL18 PTCH1 BRAF INHBA IGF2 CYP26C1 CDC42 ERCC6 VPS13A MPL RIN2 WT1 VPS13B GLI1 DUX4 FGG COL5A1 TTC12 CACNA1D TRDN CYBA TRNW ABCG5 FBN1 ARCN1 AFF4 FN1 ADAMTSL1 GATA2 TERC NSD1 KRT83 FN1 PROS1 NKX2-6 LONP1 NCF2 SMAD3 MARS2 NDUFS4 ITGB3 DLL4 DNAJC19 PLN PDE6G ROM1 SIK1 TBL2 OTX2 RNF135 RYR1 KYNU RBM8A CDKN1B TERC DSP GATA4 SCN4B DRC1 TCF3 TNFRSF1A IL1RN TULP1 TRNS1 GATA3 AIP SCN2B KCNJ5 GATA6 FBN1 GNAT2 IMPG2 SUFU CCDC114 BLOC1S3 CD55 HYMAI SMAD4 PHOX2B USB1 ZMPSTE24 ACAD8 TBXAS1 KDM6A MYH6 GLB1 SPATA5 SCNN1G VHL F13B GUSB COL3A1 CD96 PEX1 BAP1 SLMAP SMARCAL1 CTBP1 DSG1 FRG1 IL17F AMMECR1 FKRP ARHGAP31 TCOF1 MVK COX1 CLCN2 SCN5A XPA FGFR3 PTH1R AICDA UPF3B CASP10 KCNJ11 CC2D2A ECHS1 ERGIC1 CACNB2 NDUFAF1 NDUFV2 MYLK MYLK DYNC2LI1 RAG2 PKP1 STAT3 NSD1 DMD WDR35 LAT BGN TMEM43 NDUFS3 BPTF SEC23A CCDC174 CALR ICOS MYBPC3 CEP57 MRPS16 TRNT XRCC4 KIT ESS2 GNAS BCOR SUGCT ABCA4 BBS2 ESCO2 TCTN2 MRAS GP1BA MYH7 ELN CASK FSCN2 GLB1 CSF2RB SELENON BCOR ND4 KMT2D BBS4 ABCG8 HGSNAT COL2A1 BUB3 PDE8B LIPA SLC26A2 ARL3 FCGR2A FOXC2 F13A1 ATP5F1D GLA FANCI FGFR1 LYST NDUFV1 EDNRB SLC25A11 ARSA TEK ITCH WNT4 MPL SFTPA2 MMP1 IGHM SOX9 FGF8 SALL4 LZTFL1 SRD5A3 PKP2 DSP LTBP4 ACTA2 COL6A3 LEMD3 KIAA0586 MYOZ2 CTC1 SH3PXD2B NDUFS2 SH2B1 C2 LPIN2 KITLG PIK3R1 FLT4 WIPF1 DLST CASQ2 COX6B1 WDPCP HBB RAF1 LRRK2 FGFR2 COX14 TRNW EP300 FGB LFNG DNAL1 BAP1 CAPN5 ITPA SIN3A COL4A3 WDPCP HESX1 FKTN KIT PIGP WAS ZFP57 FGFR2 IL23R ATP6 DIS3L2 EFTUD2 DCHS1 FOXP1 ITGA3 CACNA1S CALR NDUFV1 CFH PEX5 USP8 DMPK CAP2 BTD ADAR BCR IL10 IFIH1 SOX10 CCDC40 GNB3 MRPL3 ERCC2 TPK1 CTSA PRKAR1A STK11 SMCHD1 HBB FKTN MEN1 ATRX TPM3 SCN1B AKT1 RRM2B KDSR DNMT3A ADAMTS10 PIK3CA CHRNA7 ND4L BMPR1A MAD2L2 ZMPSTE24 KCNH2 MED12 RP1L1 PPP2R1A APC IL12RB1 LARS2 TRNL1 POMT1 GJA8 RAF1 TANGO2 DYNC2H1 DGCR2 ALPL KIAA1109 NEK1 NODAL CAV1 PRKACA PCARE PTEN ERMARD RFWD3 PIGN KCNQ1OT1 AK2 RPL10 COL5A2 BLM KCND3 FGA RPL31 RIT1 RPL15 SLC4A1 JAG1 ACAD9 TUBB FTL TNFRSF11A PTPN22 ERCC4 PDGFB GDF1 GP6 PRKCD KIF1B ARHGEF18 TGFB3 TNNI3 PALB2 NDUFS7 PDE6D GJB3 KIT PRDM5 VHL TUBB NLRP3 SDHB STRADA PMS2 GPC6 ABCC6 TACO1 SMARCD1 SDHB HES7 TGFB3 TFAP2B TRNF RPS6KA3 IFNGR1 ALMS1 PDE6G CCDC28B PIGL CPT2 VHL FGFR3 PRDM16 PIGT MRPS22 HSPG2 MANBA TBCK HYOU1 CALR OFD1 UROS DCAF8 GDNF COG4 RREB1 HOXA13 TPM1 RUNX1 SELENON NPHP3 LBR PAH ALOX5AP WASHC5 AKR1D1 SMPD1 RFT1 PEX3 TMEM216 FAT4 RPS10 EOGT PITX2 TMCO1 HLA-DRB1 DES MEN1 ACTB KRT5 USP18 HTRA2 PEX19 ITGA2 SPATA7 NXN NID1 LMOD1 MKS1 LOX FBLN5 GATA4 COA8 MAN2B1 RASGRP1 SRY KCNJ11 KRAS SMARCB1 RECQL4 TRDN SP110 TAB2 NKX2-5 WT1 PSMD12 ACADL SLFN14 DISP1 AEBP1 SNTA1 DNAI1 SEMA4A ATP6V0A2 ACVR2B BCL11B FLAD1 RTEL1 ASCL1 CALCRL PIK3CA ATIC CCBE1 ASXL1 CDC73 SAMD9L WT1 MKS1 WDPCP F8 TBX4 UBR1 GBA SMAD4 GP1BB NEDD4L SBDS MIPEP ICOS RAD51 SLC26A2 ANO5 PEX11B BSCL2 PCNT KCNE3 EYS COL3A1 TERT SLC17A5 ADAT3 LIG4 IDUA IFT27 TWIST1 RAG2 EXT2 SMC3 HRAS MAP2K2 NDUFV2 PSEN2 ESCO2 LOX CRKL CDK4 RAG1 ITGB3 SPARC PALB2 GJA1 STXBP2 TGFB3 CBS PIGO TCOF1 TBX22 COL4A1 RLIM ADAMTS3 APC PIGL TPM3 CDH23 SCN9A NDUFS4 FOXC2 LMNA ENG SH2D1A SOX9 GATA1 TTN TMEM67 GLMN MPL LRRC6 USH2A IL12A MLH1 RP2 RPGRIP1L SETD5 IL7R MYL2 CCDC22 IFT172 IGH TKT NEXN KIF11 WNT5A ATP2C1 RPE65 PPP2CA SGCG CNTNAP2 SLC20A2 NKX2-5 PEX10 PIK3CD DHCR24 PIGW TTC25 SERPINF2 KRT18 MTFMT AKT2 HSD11B2 NDUFB9 GP1BB PHKA2 ITGA8 RNASEH2A ZNF513 TGM5 PERP PDE11A CLCN7 SMARCE1 SCNN1G CACNA1D WDR19 SLC4A1 NDUFB11 RAI1 LACC1 GM2A CYP11B1 RPL11 TNFSF15 MAB21L1 CITED2 FLNA FAT4 ANTXR1 KDM6A CLIC2 CFHR3 NUBPL SNX14 PIGY NDUFS1 LIPT1 SOX3 PSAP CPOX ND1 CD79A SLC22A5 LYZ PRPF6 FGFR2 MAPRE2 AMMECR1 LIG4 ARL6 CYSLTR2 PRPH2 CEP55 ELANE TRNC CLIC2 TSC1 FGFRL1 FUT8 ALDH18A1 DTNBP1 HABP2 TBX1 CHST3 SAA1 ATR BTK ZNF408 RSPH4A KANSL1 ERCC8 PHKG2 FHL1 PSTPIP1 HRAS CCDC65 TP53 NLRP3 NDUFS2 SPECC1L IGF2 CACNA1C GJA1 SH2B3 SYNE1 ITGA8 CYBC1 IRF8 CST3 CA2 GNAQ SCN10A MYD88 LMAN1 KRT16 VCL OTX2 SIX3 PIK3CA LMNA PLAGL1 HAVCR2 LMNA CYP11B2 MLYCD PITX2 AGGF1 AKT3 RPGRIP1L NOD2 NUMA1 DLL4 RERE MAPK1 MASP1 SPINK5 TMPO CTU2 AGTR1 TNNC1 TGFB1 CNGB1 XIAP SELENON UBR1 TRIM28 IFT140 TSPYL1 PTPN22 C2CD3 FAS RAI1 SPP1 TNFRSF11B ARMC5 PLEC IGF2 DCAF17 HLA-DPB1 PPARG PRKAG2 GLRX5 ARX SOS2 TWNK CCDC103 TRNH XYLT2 NAGS PIGV HGD RPL10 PEX14 GNA11 MYLK2 ERCC4 DMXL2 ADAMTS10 FBN1 ACTA1 CTSB REST CAV3 PEX12 FOXC1 GATA6 CAV1 CRYAB IRF8 BBS10 SRP54 DHCR24 STEAP3 ACD STN1 GCDH NDUFA12 MYH6 NSD2 BVES CD2AP LMNA SCN5A HPSE2 SCN4A POMK ALG1 CACNA1C FLNC FUCA1 COA3 G6PC HESX1 CFI RPS27 FGB ARL6 P2RY12 ABCA4 SCYL1 UMPS CAV3 LAMC2 STXBP1 SYT1 NMNAT1 TBX1 GGCX NSUN2 GJB3 RAD51C LMNA ITCH BAP1 BRCA1 ATP7A MYH6 LMNA PRTN3 NR3C2 CSPP1 WDR35 CCDC115 ZNF469 ZEB2 IDUA IMPDH1 HOXD13 TCTN2 SLC35A1 HMCN1 GAA FECH KRT10 PRCD BMP2 COX15 FGFR2 PLVAP SON RYR1 LIPC SLC25A24 FKBP14 RET AHCY KDM6A FAT4 COX15 LCAT KCNQ1OT1 RNF6 FGF17 SP7 CFAP410 NDUFA10 ACAD8 PIK3C2A NTRK1 CAV1 RNASEH2C IL17RA CDKL5 BEST1 TTN NSD1 ERCC2 EFEMP2 ABCB6 MMEL1 BUB1 ARL6 TKFC COX20 MYH7 CDKN2B UMPS GJB4 INTU CCDC22 DOLK TPM2 DSG2 H19-ICR HAMP WAS DOCK6 MYH6 HSD11B2 DNAAF1 SON AHR COL7A1 FLT4 RAG1 FKRP BRAF RASA1 PDE3A GBA KCNE1 CBL TNNT2 TRIP4 ADCY5 PHGDH PPP1CB HNRNPA1 SPTB G6PC3 RANBP2 LAMA4 CYTB MPI GDF6 SCNN1A CD19 TREX1 SCN10A KCNMB1 TOP3A SLC39A4 WWOX HADHA IGHM MYH11 TBX5 PET100 COL1A1 NAGA PTEN ABCA1 GNE GLI3 TXNRD2 TNFRSF11A NKX2-5 PDCD10 HSPG2 FBLN5 SCNN1B MYPN PROS1 SCAPER NPPA SCN1B CD19 FKBP14 WARS2 TTN ZNF148 ARL2BP FRAS1 HIBCH SDHC FANCF NECTIN1 PEX6 TBX3 TGFB2 MESP2 COX3 DOCK8 HYLS1 NRAS SCN3B ZIC2 MYO5B KAT6A MECP2 RSPO2 SGCB SPEF2 CCND1 NIPBL CALM2 F5 YY1 SLC2A10 KIF1B AIP ALDH18A1 INS TNFRSF1A MBTPS2 HBG2 TWNK ABCC8 RPL15 TRAF7 PIGN FGFR1 TBX20 KCNJ2 ZAP70 SFTPA1 SPTA1 ACTA1 EPAS1 SPECC1L TFR2 DSG2 ANO10 RTEL1 PROKR2 ABCA12 CBL HACD1 TRIM8 POMT2 TNPO3 TXNRD2 SLC29A3 TRNN ACAD9 ADAMTSL2 TSC2 ND4L CEP290 DSP ZNF423 FMO3 NDUFAF4 DPF2 FOXP3 DACT1 CRYAB TWNK SF3B1 GNE SMOC1 NR3C1 SULT2B1 TERT KLLN BAG3 ELANE YARS2 TRNF GAS2L2 XPA LMX1B PRKACG KCNJ5 IDH3A AKAP10 MC2R RASA2 DHCR7 RBP4 HJV B9D2 RASGRP1 RHO LDLRAP1 NRXN1 SH2B3 PRPF3 TMEM237 KIF7 KIAA0753 LMNA KLF13 MUC5B RLBP1 TSR2 TSPYL1 NNT HNF4A TP53 TKFC LMNA NDUFA2 VIPAS39 FOXC1 ANKRD11 KCNJ8 KDM1A IFIH1 LRP5 MOG EIF2AK4 HBB SDHA XYLT1 AIP PACS1 SRSF2 PTPN11 CPN1 PLOD1 SGCD DNAH9 CACNA2D1 TMEM43 F9 FSHR WHCR COL1A1 ELOVL4 NLRP3 TGDS HMBS HCCS TREX1 SOX18 CEP19 DNASE1 DES ACADVL CYLD ROM1 NOTCH2 SCN5A WT1 DGUOK IFT88 FERMT1 VAC14 KIF1B PIK3R1 USF3 GYG1 DNAJC21 LIPA CCNQ COL1A2 CDAN1 SDHA FXN PEX3 POMT2 CD109 EIF2AK3 PSAT1 ENG TTN SKI IDUA PRPF31 KRIT1 CLEC7A NEXN KPTN MRE11 MAP1B DKC1 RPL26 GATA1 PDE6A ARID2 TET2 TET2 HBA2 FUCA1 GABRA3 ALOX12B CCDC39 PLIN1 FGFR3 ATRX HAAO FMR1 MYH7 BACH2 SGSH ARID1B PTEN STK11 SCN1B KCNK3 SOX9 GPC3 EDA2R OSTM1 CTLA4 TNNI3 PDGFRA GATA6 SFTPC KCNQ1 BOLA3 CBL APOE TTC37 CHD7 HSPG2 COX7B MTRR STN1 RNASEH2A MCCC2 NFIX PROC CYP11B2 MSH2 IL6 POLG2 CCND1 NCAPG2 ATP7A STX3 GAS8 DGCR8 LMNA TRIM32 GIGYF2 TCF4 AKT1 TRNK TMC6 RASA1 HPS3 HRAS FGA SETBP1 IRF2BP2 HIBCH SLC35A2 TFAP2A SEMA3E PIGQ CHST14 PLEC ACTN2 CHRND INPP5E PKLR GINS1 CRYAB PEX10 NEK1 ESCO2 ECE1 AGBL5 WRN DVL1 KLHL3 BRAF NKX2-5 POU6F2 DAXX C4A DES ALDH18A1 RPS28 FLCN COL4A2 PSMB8 TCAP LAMA4 FANCA DMD KLHL7 DGCR6 WFS1 NCF4 RAG1 TPP2 ADD1 RAB23 F5 SGCG XRCC2 TMEM67 NKX2-5 CDON B2M CRTAP TP53 PIK3R2 DCAF17 FKRP GATA6 SUFU ERCC4 ALX4 OFD1 ATAD3A DCLRE1C SCNN1B ACAT1 MBTPS2 CACNA2D1 TPM1 ND5 LARP7 MUC5B NDUFS8 LIAS SP110 FAS MYH3 DPM3 PIGY BAP1 FANCM ETHE1 DHDDS KCNJ5 SNX10 ERCC6 NKX2-5 MEN1 GPC4 HNF1A XRCC4 TET2 FHL1 MUC1 RYR2 DGUOK DNMT3B ARMC9 SDHB POMT1 MAP2K2 NCF1 RBM20 CLIP2 ALX3 POR IFNG DCDC2 STAT4 HLA-DRB1 PRKACA F2 KCNN4 PLEKHM1 MAFB NDUFS2 PKLR PCGF2 NEU1 GTPBP3 NOTCH1 HIRA DKC1 KCNQ1 STEAP3 AKT1 RNF125 TGFBR2 FGA CPLX1 WFS1 AIP TGFBR1 MYL2 GNAO1 DYNC2I2 SOS1 CYP24A1 MYH7 RERE DNAJB13 TBC1D24 HLA-B SDHD WNT3 BRCA2 SERPIND1 FLNC PROKR2 TRNL1 DDB2 GREM1 ANAPC1 GPD1L RIN2 FBN1 SMAD6 ND3 TGFBR2 RYR2 ND6 MED12 COL4A1 NOTCH3 CCNO AGXT PIBF1 SLC26A3 CR2 IL2RA SLC7A7 NDUFA4 CAVIN1 PROC KCNQ1 TPM3 IGF1R ANKRD26 PEPD GJA1 BAG3 LYST KDM5B SLC25A11 ALG8 ATP6V0A2 ERBB3 RPL27 ACTN4 ADA2 PMM2 RET DYRK1B COL2A1 TRNL1 POLR3A EPB42 BMPR2 GNB5 ND1 CRELD1 PIK3CA RNU4ATAC MSX1 GPC6 MGP PSAP IFT172 NDUFB8 VHL ANKRD1 KCNQ1 NGLY1 PPP1CB KRAS MITF SCN5A SALL4 TRAPPC11 ALB ERCC5 ATRX EPB41 PHOX2B CTNNA3 CFAP221 RNU4ATAC B3GALT6 SDHD LAMA3 ZIC3 GGCX B3GLCT RAI1 SALL1 CDKN1B F2 STK36 BBS5 IDH3B CAV3 NEUROG3 PUF60 TRPM4 DHX37 SDHC MALT1 SDHD ATPAF2 TXNL4A KRT2 HS6ST1 PSAP DDRGK1 KCNE2 NME8 TRNE ND1 UBE3B COQ2 BMP2 NAXD LMNA COX10 FKRP MKKS CYP17A1 TRDN THBD BTNL2 EYA4 TGM5 BCL10 FBN1 TNFRSF13C PDGFB ALG9 FANCC LIG4 ACTA2 FLNA TCTN3 GNAS IKBKG PRKG1 SERPINA6 AGTR1 CFB GDNF POMP KAT6B NHLRC2 TRMU KCNJ2 RPGR HADHA FANCB PKD1 FANCD2 SCN9A TCIRG1 ZIC3 SCN9A SLC39A4 POLG ADA LIPN KCNE1 CERKL GCH1 BAZ1B CYP7B1 PCSK9 SFTPB PTH1R CTLA4 BCOR LRP5 PPCS DYNC2LI1 TGM1 ASS1 PPCS GYPC MPL COL1A1 COL4A5 TP63 CFC1 TSHR NONO COA8 ACTG1 MYH7 CLPB SCN5A THSD1 PIGA ARID1B DNAAF2 NPHP4 JAG1 BAP1 CRLF1 NOS3 MMUT KIT FAH SRD5A3 CDK8 STAT1 IFNG SDCCAG8 MED25 PAX3 HCN4 CRYAB KIF15 RNF113A GNPTAB ACTG1 IRX5 ZMYND10 PIGL SEC23A PIK3R2 AIRE MYH7 AIRE SF3B4 PIGV FMR1 TXNL4A COL1A2 PIK3CA AKT1 AAAS NFIX GBA PACS2 DIS3L2 KRAS DNAJC19 KRAS JUP APP ALG1 NDUFA1 ACTA2 DLL3 NDUFA11 CYP17A1 NOTCH1 TNFRSF13B CASR FLII LDB3 CHRNA1 TRPM4 C12ORF57 AKAP9 MC1R ATP6 CSRP3 NSMF IL10RA BBS1 CUL7 TOPORS NDUFS2 OPA1 TSC1 SLC40A1 ATP6V1A FBN1 HMBS FHL1 CTCF PRKCH C8ORF37 SPTA1 DLD F8 CXCR4 ARL3 GDF6 LRAT PEX7 GATA6 ADK SLC20A2 ABCC6 FGF23 AGPAT2 ATP5F1E CTLA4 ATP6V1E1 FANCA SUMF1 DSP OTX2 OFD1 CD27 CASP8 RPS19 POMGNT1 KCNJ5 TNFSF12 SPINK5 MPL STIM1 PNPLA2 SLC19A2 CFHR3 RPS19 POMT1 FCGR2A NEXN FEZF1 SUFU TP63 BAG3 NOS3 LIPA NKX2-1 DNAJC13 TMEM231 TTR MPLKIP VHL LRP1 BIRC3 ESR1 FBN2 FANCL EPB42 GNAS LAMP2 DDX59 ND2 RAF1 MAP3K7 ITGA2B PEX7 IL12A-AS1 MLX FGFR2 PCCB TJP2 MED13L PORCN CD81 MRPS14 THPO MYRF MRPL44 HAMP KRT5 CTNNB1 MMP14 KLF1 TRNT1 DBH TRPM4 SERPING1 PCNA TERT BRAF PET100 HLA-DQB1 TNNT2 PRKCSH AEBP1 EVC PEX6 ACVRL1 TELO2 COL2A1 FADD GCLC FIBP KCNQ1 TAF2 RGR FADD SNIP1 SCO2 NDUFS2 NDUFB11 SLC25A22 KCNE3 MRAP ADGRE2 CACNA1S VPS33A HSPA9 NF1 SNCA FLI1 CD46 OTULIN CLDN1 GAS1 FASLG COX3 FANCB LMNA C2CD3 MTHFR ROR2 PQBP1 GATA1 SDHA SMAD4 SNRPB MEGF8 CYP7A1 KIAA0319L KCNE2 AP3D1 PEX1 COQ4 ATM ARVCF BPGM CRX RAG2 CKAP2L INVS NFKB2 KIF5A JAK2 KIF7 TGIF1 FOXRED1 SOX3 FKTN IQSEC2 DMD COL4A1 LAMB3 TNFSF11 SDHC RBPJ HBG1 KCNQ1 NDUFAF4 CISD2 IL2RG PLAU F5 TBX2 RNASEH2B GMPPB SCN11A GLRX5 MAF PLN VPS45 NPM1 ND5 USB1 PEX16 NOS3 ELN SLC2A1 STAG1 HADHA MYH11 RBM10 STAR PORCN MYH7 MYH9 NKX2-5 RET GSN CDKN2A PSMD12 MYPN NOTCH3 GJA1 NCF2 SLC39A13 MEIS2 FOXC1 IDH1 PRPF8 FOXP1 SOX10 RNASEH1 ERCC4 NDUFS8 ND5 STIM1 CYP11B1 MEF2A ACTA2 ATP7A TERC ELN GPX4 PMPCA EMD VAMP7 GLB1 JMJD1C SYNE1 VANGL1 RPL5 CEP120 IVD NLRP3 PKD2 FLNA MED13L AUTS2 TRIP13 GNAI2 CACNA1S NRL FLNA CARD11 NAA10 TMEM126B POLR1C COL1A2 PROC STK4 SDHB SCO2 BUB1B SCN2B PTPN11 DLX5 SOX4 GNPTG JAK2 MTMR14 NR5A1 YY1AP1 NDUFAF2 RMRP ARID1A CSNK2A1 USH2A TCTN3 SETD5 CPT2 SF3B1 TK2 TRNW SCNN1G SOX2 TBX1 SPRY2 NOTCH1 CPT1A JAK2 NDUFA2 TRAF3IP1 CFAP298 P2RY11 CEP290 SERPINC1 TMEM67 KCNJ18 FZD4 GBA NGLY1 SEC24C COL2A1 MECP2 MAX ATP6 TMEM107 FGFR2 FGFR2 FTO LMBR1 HADHB DSP COL7A1 RB1 SLC25A4 CLRN1 MEIS2 SNRNP200 RIPPLY2 CYBA SHANK3 GDF1 NDUFAF5 TMEM237 NOTCH2 NAGA SMARCC2 SDHAF2 STAG2 PEX19 CD81 PDGFRA SIM1 TRNE FHL1 PPARG PARS2 SGCA ZFPM2 SMG9 CLCF1 TMEM127 ETV6 TTC7A NIPBL IDH2 GTF2H5 GMPPB RPGR SCNN1B PHYH CAV1 ENPP1 COX1 PEX26 SCARB2 HFE KCNA5 PEX5 ACVRL1 ARL2BP NFE2L2 INTS1 CYP11B1 SYNE2 AKT1 IL17RD TTN FGFR2 ABCC9 TRIP13 RAG1 ITGA2B CFAP300 RIPK4 PRPF3 PAX6 SMC3 ALDH18A1 IDH2 RHBDF2 TTC37 CD28 FARSB LRP5 NPC2 RERE SELENOI BMPR2 NRXN1 SCN5A ZMYND10 TMEM67 RBBP8 TRIP11 LZTR1 COL3A1 FREM2 SALL1 ATP6 CYP27A1 NUP107 PLIN1 NKX2-5 IKZF1 PEX13 POLG AKAP9 EXT2 RARA TPM2 NEK10 ARMC4 AGT LIG4 UBE2A SSR4 EGFR APOC2 SLC2A10 RPS6KA3 MAP2K1 PDGFB PTEN ND1 CEP120 GJB6 RDH5 ABHD5 NDP AHI1 ISCU SERPING1 PNP COL3A1 ITGA7 NDUFB11 NPHP3 TRNK HLA-DPA1 NEK8 RARB PLN PRKAR1A SLC25A13 TLL1 HLA-A CNBP DVL3 NLRP3 MAF ADNP LBR TANGO2 PKHD1 ATP6V1A FANCD2 SNCA BICC1 SBDS FAM149B1 ACADS BMPR1A COX2 GTF2I MID1 MVK KIF23 MYBPC3 DNASE1L3 KCNE5 THOC2 FGFR3 FLNA IFNGR1 ISG15 PEX6 TP63 D2HGDH LTBP2 DDX58 EZH2 IDH3B F8 SLC29A3 TBX6 NF1 SOX10 STAT3 SCYL1 TMEM260 ATAD3A HLA-B GLI2 ITPR1 PTPN22 SCNN1A EBP COL7A1 EDN3 LDB3 BIN1 WT1 LIPC ABCD4 HPS1 PROK2 SIM1 WASHC5 LPL SLC12A3 PHF21A CYP27A1 ARNT2 HNRNPU STING1 FIG4 FANCC GUCY1A1 PTPN14 SIK3 IRF6 POLD1 SDHB TMEM216 ACTA1 PEX14 PRKAG2 NR3C1 SUZ12 DNAAF3 HBA1 IGF2 GJA5 MYPN SETX ND2 POLH CYBB CALM2 KCTD1 FSCN2 HADHA TCIRG1 SEMA3A GP9 AP1B1 LYST LMNA TMEM231 TNXB CDH23 IL7R BTK SARS2 ELN STAC3 FLNA SMAD4 MAP3K20 PGAP3 FOXE3 NFU1 MKS1 MYH11 MCFD2 ACTB FECH FLI1 PUF60 KRAS

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook